Alharbi, KS, Afzal, O, almalki, WH, Kazmi, I, Javed Shaikh, MA, Thangavelu, L, Gulati, M, Singh, SK, Jha, NK, Gupta, PK, Chellappan, DK, Oliver, BG, Dua, K & Gupta, G 2022, 'Nuclear factor-kappa B (NF-κB) inhibition as a therapeutic target for plant nutraceuticals in mitigating inflammatory lung diseases', Chemico-Biological Interactions, vol. 354, pp. 109842-109842.
View/Download from: Publisher's site
Alharbi, KS, Ali, T, Singh, Y, Ali Al-Ghamdi, AS, Kazmi, I, Al-Abbasi, FA, Alzarea, SI, Afzal, O, Alfawaz Altamimi, AS, Singh, SK, Chellappan, DK, Dua, K & Gupta, G 2022, 'Biochemical interaction of pyrvinium in gentamicin-induced acute kidney injury by modulating calcium dyshomeostasis and mitochondrial dysfunction', Chemico-Biological Interactions, vol. 363, pp. 110020-110020.
View/Download from: Publisher's site
Alharbi, KS, Almalki, WH, Albratty, M, Meraya, AM, Najmi, A, Vyas, G, Singh, SK, Dua, K & Gupta, G 2022, 'The therapeutic role of nutraceuticals targeting the Nrf2/ HO ‐1 signaling pathway in liver cancer', Journal of Food Biochemistry, vol. 46, no. 10.
View/Download from: Publisher's site
Alharbi, KS, Almalki, WH, Alzarea, SI, Kazmi, I, Al-Abbasi, FA, Afzal, O, Alfawaz Altamimi, AS, Singh, SK, Dua, K & Gupta, G 2022, 'A narrative review on the biology of piezo1 with platelet-rich plasma in cardiac cell regeneration', Chemico-Biological Interactions, vol. 363, pp. 110011-110011.
View/Download from: Publisher's site
Alharbi, KS, Almalki, WH, Makeen, HA, Albratty, M, Meraya, AM, Nagraik, R, Sharma, A, Kumar, D, Chellappan, DK, Singh, SK, Dua, K & Gupta, G 2022, 'Role of Medicinal plant‐derived Nutraceuticals as a potential target for the treatment of breast cancer', Journal of Food Biochemistry, vol. 46, no. 12.
View/Download from: Publisher's site
Alharbi, KS, Javed Shaikh, MA, Afzal, O, Alfawaz Altamimi, AS, Almalki, WH, Alzarea, SI, Kazmi, I, Al-Abbasi, FA, Singh, SK, Dua, K & Gupta, G 2022, 'An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy', Chemico-Biological Interactions, vol. 366, pp. 110108-110108.
View/Download from: Publisher's site
Alharbi, KS, Javed Shaikh, MA, Afzal, O, Alfawaz Altamimi, AS, Hassan almalki, W, Kazmi, I, Al-Abbasi, FA, Alzarea, SI, Babu, MR, Singh, SK, Chellappan, DK, Dua, K & Gupta, G 2022, 'Oligonucleotides: A novel area of interest for drug delivery in neurodegenerative diseases', Journal of Drug Delivery Science and Technology, vol. 77, pp. 103849-103849.
View/Download from: Publisher's site
Alharbi, KS, Shaikh, MAJ, Almalki, WH, Kazmi, I, Al-Abbasi, FA, Alzarea, SI, Imam, SS, Alshehri, S, Ghoneim, MM, Singh, SK, Chellappan, DK, Oliver, BG, Dua, K & Gupta, G 2022, 'PI3K/Akt/mTOR Pathways Inhibitors with Potential Prospects in Non-Small-Cell Lung Cancer', Journal of Environmental Pathology, Toxicology and Oncology, vol. 41, no. 4, pp. 85-102.
View/Download from: Publisher's site
View description>>
Lung cancer is the leading cause of cancer-related mortality across the globe. The most prevalent pathological form of lung cancer is non-small-cell lung cancer (NSCLC). Elevated stimulation of the PI3K/Akt/mTOR pathway causes a slew of cancer-related symptoms, making it a promising target for new anticancer drugs. The PI3K/Akt/mTOR path is involved extensively in carcinogenesis and disease advancement in NSCLC. Several new inhibitors targeting this pathway have been discovered in preclinical investigations and clinical trials. The etiology and epidemiology of NSCLC and biology of the PI3K/Akt/mTOR cascade and its role in NSCLC pathogenesis have all been discussed in this article. In this article, we've reviewed PI3K/Akt/mTOR cascade inhibitors that have been proven in vitro and in preclinical trials to be effective in NSCLC. Drugs targeting the PI3K/Akt/mTOR path in the treatment of NSCLC were also addressed. A better knowledge of the underlying molecular biology, including epigenetic changes, is also critical to detecting relevant biomarkers and guiding combination methods. Additionally, improved clinical trial designs will increase the capacity to test novel drugs and combinations for accounting for genomic variation and eventually improve patient outcomes.
Alharbi, KS, Singh, Y, Afzal, O, Alfawaz Altamimi, AS, Kazmi, I, Al-Abbasi, FA, Alzarea, SI, Chellappan, DK, Singh, SK, Dua, K & Gupta, G 2022, 'Molecular explanation of Wnt/βcatenin antagonist pyrvinium mediated calcium equilibrium changes in aging cardiovascular disorders', Molecular Biology Reports, vol. 49, no. 11, pp. 11101-11111.
View/Download from: Publisher's site
View description>>
The symptoms of ageing are somewhat different and can lead to the altered role of the cardiovascular system at the levels of genetic, biochemical, tissue, organ, and systems. Ageing is an autonomous cardiovascular risk factor. In the ageing rat heart, oxidative and inflammatory stress, immune cell infiltration, increasing myeloperoxidase function, elevated caspase-3 activity, and protein fibronectins were detected and associated with ageing and cardiovascular disease. The intracellular Ca2 + homeostasis disturbed in an older heart dramatically increases cardiomyopathy, atherosclerosis, stroke, ischemia, myocardial infarction, hypertrophy, remodelling, and hypertension. Evidence shows that suppression of Wnt/β signals prevents cardiovascular dysfunction, such as remodelling, high blood pressure, and excessive overload stress. However, one study has shown that the pharmacological disruption of Wnt-β-catenin by decreasing expression of α-smooth muscle actin, fibronectin and collagen I proteins attenuates angiotensin II mediated hypertension cardiac fibrosis. Thus, this review examined the impacts of calcium overload and age-related diseases, including cardiovascular. Energy dysregulation, calcium overloading, and mitochondrial dysfunction are the main activities causing cardiovascular disease linked with age. Therefore, the current study explores that age-associated cardiovascular disease has triggered the WNT/β-catenin pathway, and pharmacological inhibition can delay pathological changes by attenuating calcium dyshomeostasis.
Alharbi, KS, Singh, Y, Hassan almalki, W, Rawat, S, Afzal, O, Alfawaz Altamimi, AS, Kazmi, I, Al-Abbasi, FA, Alzarea, SI, Singh, SK, Bhatt, S, Chellappan, DK, Dua, K & Gupta, G 2022, 'Gut Microbiota Disruption in COVID-19 or Post-COVID Illness Association with severity biomarkers: A Possible Role of Pre / Pro-biotics in manipulating microflora', Chemico-Biological Interactions, vol. 358, pp. 109898-109898.
View/Download from: Publisher's site
Ali, MK, Schimmel, K, Zhao, L, Chen, C-K, Dua, K, Nicolls, MR & Spiekerkoetter, E 2022, 'The role of circular RNAs in pulmonary hypertension', European Respiratory Journal, vol. 60, no. 6, pp. 2200012-2200012.
View/Download from: Publisher's site
View description>>
Circular RNAs (circRNAs) are endogenous, covalently circularised, non-protein-coding RNAs generated from back-splicing. Most circRNAs are very stable, highly conserved, and expressed in a tissue-, cell- and developmental stage-specific manner. circRNAs play a significant role in various biological processes, such as regulation of gene expression and protein translationviasponging of microRNAs and binding with RNA-binding proteins. circRNAs have become a topic of great interest in research due to their close link with the development of various diseases. Their high stability, conservation and abundance in body fluids make them promising biomarkers for many diseases. A growing body of evidence suggests that aberrant expression of circRNAs and their targets plays a crucial role in pulmonary vascular remodelling and pulmonary arterial hypertension (group 1) as well as other forms (groups 3 and 4) of pulmonary hypertension (PH). Here we discuss the roles and molecular mechanisms of circRNAs in the pathogenesis of pulmonary vascular remodelling and PH. We also highlight the therapeutic and biomarker potential of circRNAs in PH.
Allam, VSRR, Chellappan, DK, Jha, NK, Shastri, MD, Gupta, G, Shukla, SD, Singh, SK, Sunkara, K, Chitranshi, N, Gupta, V, Wich, PR, MacLoughlin, R, Oliver, BGG, Wernersson, S, Pejler, G & Dua, K 2022, 'Treatment of chronic airway diseases using nutraceuticals: Mechanistic insight', Critical Reviews in Food Science and Nutrition, vol. 62, no. 27, pp. 7576-7590.
View/Download from: Publisher's site
View description>>
Respiratory diseases, both acute and chronic, are reported to be the leading cause of morbidity and mortality, affecting millions of people globally, leading to high socio-economic burden for the society in the recent decades. Chronic inflammation and decline in lung function are the common symptoms of respiratory diseases. The current treatment strategies revolve around using appropriate anti-inflammatory agents and bronchodilators. A range of anti-inflammatory agents and bronchodilators are currently available in the market; however, the usage of such medications is limited due to the potential for various adverse effects. To cope with this issue, researchers have been exploring various novel, alternative therapeutic strategies that are safe and effective to treat respiratory diseases. Several studies have been reported on the possible links between food and food-derived products in combating various chronic inflammatory diseases. Nutraceuticals are examples of such food-derived products which are gaining much interest in terms of its usage for the well-being and better human health. As a consequence, intensive research is currently aimed at identifying novel nutraceuticals, and there is an emerging notion that nutraceuticals can have a positive impact in various respiratory diseases. In this review, we discuss the efficacy of nutraceuticals in altering the various cellular and molecular mechanisms involved in mitigating the symptoms of respiratory diseases.
Allam, VSRR, Paudel, KR, Gupta, G, Singh, SK, Vishwas, S, Gulati, M, Gupta, S, Chaitanya, MVNL, Jha, NK, Gupta, PK, Patel, VK, Liu, G, Kamal, MA, Hansbro, PM, Oliver, BGG, Chellappan, DK & Dua, K 2022, 'Nutraceuticals and mitochondrial oxidative stress: bridging the gap in the management of bronchial asthma', Environmental Science and Pollution Research, vol. 29, no. 42, pp. 62733-62754.
View/Download from: Publisher's site
View description>>
AbstractAsthma is a chronic inflammatory disease primarily characterized by inflammation and reversible bronchoconstriction. It is currently one of the leading causes of morbidity and mortality in the world. Oxidative stress further complicates the pathology of the disease. The current treatment strategies for asthma mainly involve the use of anti-inflammatory agents and bronchodilators. However, long-term usage of such medications is associated with severe adverse effects and complications. Hence, there is an urgent need to develop newer, novel, and safe treatment modalities for the management of asthma. This has therefore prompted further investigations and detailed research to identify and develop novel therapeutic interventions from potent untapped resources. This review focuses on the significance of oxidative stressors that are primarily derived from both mitochondrial and non-mitochondrial sources in initiating the clinical features of asthma. The review also discusses the biological scavenging system of the body and factors that may lead to its malfunction which could result in altered states. Furthermore, the review provides a detailed insight into the therapeutic role of nutraceuticals as an effective strategy to attenuate the deleterious effects of oxidative stress and may be used in the mitigation of the cardinal features of bronchial asthma.
Anand, K, Ramesh, M, Singh, T, Balakumar, C, Chithravel, V, Prasher, P, Katari, NK, Gupta, G, Singh, SK, Chellappan, DK, Dua, K, Chavda, V, Laishevtcev, A, Shahbaaz, M, Abdellattif, MH, Saravanan, M & Chuturgoon, AA 2022, 'One-step synthesis of picolinohydrazides from fusaric acid: DFT, structural characterization and molecular inhibitory studies on metastatic tumor-derived exosomal and non-exosomal proteins', Journal of Molecular Structure, vol. 1255, pp. 132442-132442.
View/Download from: Publisher's site
Arora, P, Nainwal, LM, Gupta, G, Singh, SK, Chellappan, DK, Oliver, BG & Dua, K 2022, 'Orally administered solasodine, a steroidal glycoalkaloid, suppresses ovalbumin-induced exaggerated Th2-immune response in rat model of bronchial asthma', Chemico-Biological Interactions, vol. 366, pp. 110138-110138.
View/Download from: Publisher's site
Ashique, S, De Rubis, G, Sirohi, E, Mishra, N, Rihan, M, Garg, A, Reyes, R-J, Manandhar, B, Bhatt, S, Jha, NK, Singh, TG, Gupta, G, Singh, SK, Chellappan, DK, Paudel, KR, Hansbro, PM, Oliver, BG & Dua, K 2022, 'Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases', Chemico-Biological Interactions, vol. 368, pp. 110231-110231.
View/Download from: Publisher's site
Ashique, S, Upadhyay, A, Garg, A, Mishra, N, Hussain, A, Negi, P, Hing, GB, Bhatt, S, Ali, MK, Gowthamarajan, K, Singh, SK, Gupta, G, Chellappan, DK & Dua, K 2022, 'Impact of ecDNA: A mechanism that directs tumorigenesis in cancer drug Resistance-A review', Chemico-Biological Interactions, vol. 363, pp. 110000-110000.
View/Download from: Publisher's site
Ashique, S, Upadhyay, A, Hussain, A, Bag, S, Chaterjee, D, Rihan, M, Mishra, N, Bhatt, S, Puri, V, Sharma, A, Prasher, P, Singh, SK, Chellappan, DK, Gupta, G & Dua, K 2022, 'Green biogenic silver nanoparticles, therapeutic uses, recent advances, risk assessment, challenges, and future perspectives', Journal of Drug Delivery Science and Technology, vol. 77, pp. 103876-103876.
View/Download from: Publisher's site
Awasthi, A, Gulati, M, Kumar, B, Kaur, J, Vishwas, S, Khursheed, R, Porwal, O, Alam, A, KR, A, Corrie, L, Kumar, R, Kumar, A, Kaushik, M, Jha, NK, Gupta, PK, Chellappan, DK, Gupta, G, Dua, K, Gupta, S, Gundamaraju, R, Rao, PV & Singh, SK 2022, 'Recent Progress in Development of Dressings Used for Diabetic Wounds with Special Emphasis on Scaffolds', BioMed Research International, vol. 2022, no. 1, pp. 1-43.
View/Download from: Publisher's site
View description>>
Diabetic wound (DW) is a secondary application of uncontrolled diabetes and affects about 42.2% of diabetics. If the disease is left untreated/uncontrolled, then it may further lead to amputation of organs. In recent years, huge research has been done in the area of wound dressing to have a better maintenance of DW. These include gauze, films, foams or, hydrocolloid‐based dressings as well as polysaccharide‐ and polymer‐based dressings. In recent years, scaffolds have played major role as biomaterial for wound dressing due to its tissue regeneration properties as well as fluid absorption capacity. These are three‐dimensional polymeric structures formed from polymers that help in tissue rejuvenation. These offer a large surface area to volume ratio to allow cell adhesion and exudate absorbing capacity and antibacterial properties. They also offer a better retention as well as sustained release of drugs that are directly impregnated to the scaffolds or the ones that are loaded in nanocarriers that are impregnated onto scaffolds. The present review comprehensively describes the pathogenesis of DW, various dressings that are used so far for DW, the limitation of currently used wound dressings, role of scaffolds in topical delivery of drugs, materials used for scaffold fabrication, and application of various polymer‐based scaffolds for treating DW.
Awasthi, A, Kumar, A, Kumar, R, Vishwas, S, Khursheed, R, Kaur, J, Corrie, L, Kumar, B, Gulati, M, Kumar, D, Kaushik, M, Gupta, G, Prasher, P, Chellappan, DK, Kumar, AP, Dua, K & Singh, SK 2022, 'RP-HPLC method development and validation for simultaneous estimation of mesalamine and curcumin in bulk form as well as nanostructured lipid carriers', South African Journal of Botany, vol. 151, pp. 529-537.
View/Download from: Publisher's site
Awasthi, A, Kumar, B, Gulati, M, Vishwas, S, Corrie, L, Kaur, J, Khursheed, R, Muhammed, RA, Kala, D, Porwal, O, Babu, MR, Chaitanya, MVNL, Kumar, A, Pandey, NK, Dureja, H, Chellappan, DK, Jha, NK, Gupta, G, Prasher, P, Kumar, D, Dua, K & Singh, SK 2022, 'Novel Nanostructured Lipid Carriers Co-Loaded with Mesalamine and Curcumin: Formulation, Optimization and In Vitro Evaluation', Pharmaceutical Research, vol. 39, no. 11, pp. 2817-2829.
View/Download from: Publisher's site
Awasthi, A, Vishwas, S, Gulati, M, Corrie, L, Kaur, J, Khursheed, R, Alam, A, Alkhayl, FFA, Khan, FR, Nagarethinam, S, Kumar, R, Arya, KR, Kumar, B, Chellappan, DK, Gupta, G, Dua, K & Singh, SK 2022, 'Expanding arsenal against diabetic wounds using nanomedicines and nanomaterials: Success so far and bottlenecks', Journal of Drug Delivery Science and Technology, vol. 74, pp. 103534-103534.
View/Download from: Publisher's site
Awasthi, R, Singh, AK, Maurya, A, Mishra, G, Dua, K & Kulkarni, GT 2022, 'Nanovaccine: A Hope to Triumph the Battle Against Novel CoronavirusDisease 2019 (COVID-19)', Recent Patents on Nanotechnology, vol. 17, no. 1, pp. 15-17.
View/Download from: Publisher's site
View description>>
Background:The novel coronavirus 2019 (COVID-19) infection has caused the globalemergence of coronavirus in humans during the last 12 months. Till May 11, 2021, the confirmedglobal COVID-19 cases and deaths reached 158551526 and 3296855, respectively.Methods:Goblet cells and ciliated cells in the nose act as the initial infection site of SARS-CoV-2.Thus, mucus immunity is important to protect from infection. The outburst of SARS-CoV-2 infectioncan be halted only when an effective vaccine will be developed.Results:Globally, over 100 different vaccines are under investigation, including DNA vaccines, RNAvaccines, inactivated virus vaccines, adenovirus-based vaccines, recombinant/subunit protein vaccines,peptide vaccines, virus-like particles, etc. Inactivated virus vaccines and mRNA, and adenovirus-basedvaccines have moved fast into clinical trials.Conclusion:Vaccines containing spike protein of SARS-CoV as subunit could effectively preventbinding of coronavirus to the host cell and membrane fusion. Thus, spike protein can be used as a majortarget for subunit vaccine preparation.
Bhardwaj, S, Kesari, KK, Rachamalla, M, Mani, S, Ashraf, GM, Jha, SK, Kumar, P, Ambasta, RK, Dureja, H, Devkota, HP, Gupta, G, Chellappan, DK, Singh, SK, Dua, K, Ruokolainen, J, Kamal, MA, Ojha, S & Jha, NK 2022, 'CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics', Journal of Advanced Research, vol. 40, pp. 207-221.
View/Download from: Publisher's site
View description>>
Background: Alzheimer's disease (AD) is an insidious, irreversible, and progressive neurodegenerative health condition manifesting as cognitive deficits and amyloid beta (Aβ) plaques and neurofibrillary tangles. Approximately 50 million individuals are affected by AD, and the number is rapidly increasing globally. This review explores the role of CRISPR/Cas9 gene editing in the management of AD and its clinical manifestations. Aim of Review: This review aims to provide a deep insight into the recent progress in CRISPR/Cas9-mediated genome editing and its use against neurodegenerative disorders, specifically AD. However, we have referred to its use against parkinsons's disease (PD), Huntington's disease (HD), and other human diseases, as is one of the most promising and emerging technologies for disease treatment. Key Scientific Concepts of Review: The pathophysiology of AD is known to be linked with gene mutations, that is, presenilin (PSEN) and amyloid beta precursor protein (APP). However, clinical trials focused at the genetic level could not meet the desired efficiency. The CRISPR/Cas9 genome editing tool is one of the most powerful technologies for correcting inconsistent genetic signatures and now extensively used for AD management. It has significant potential for the correction of undesired gene mutations associated with AD. This technology has allowed the development of empirical AD models, therapeutic lines, and diagnostic approaches for better understanding the nervous system, from in vitro to in vivo models.
Bhat, AA, Gupta, G, Alharbi, KS, Afzal, O, Altamimi, ASA, Almalki, WH, Kazmi, I, Al-Abbasi, FA, Alzarea, SI, Chellappan, DK, Singh, SK, MacLoughlin, R, Oliver, BG & Dua, K 2022, 'Polysaccharide-Based Nanomedicines Targeting Lung Cancer', Pharmaceutics, vol. 14, no. 12, pp. 2788-2788.
View/Download from: Publisher's site
View description>>
A primary illness that accounts for a significant portion of fatalities worldwide is cancer. Among the main malignancies, lung cancer is recognised as the most chronic kind of cancer around the globe. Radiation treatment, surgery, and chemotherapy are some medical procedures used in the traditional care of lung cancer. However, these methods lack selectivity and damage nearby healthy cells. Several polysaccharide-based nanomaterials have been created to transport chemotherapeutics to reduce harmful and adverse side effects and improve response during anti-tumour reactions. To address these drawbacks, a class of naturally occurring polymers called polysaccharides have special physical, chemical, and biological characteristics. They can interact with the immune system to induce a better immunological response. Furthermore, because of the flexibility of their structures, it is possible to create multifunctional nanocomposites with excellent stability and bioavailability for the delivery of medicines to tumour tissues. This study seeks to present new views on the use of polysaccharide-based chemotherapeutics and to highlight current developments in polysaccharide-based nanomedicines for lung cancer.
Bhat, AA, Gupta, G, Singh, SK, Yadav, HKS, Saini, M, Salfi, R, Singh, SK & Dua, K 2022, 'Nanotechnology-Based Advancements In NF-κB Pathway Inhibition for the Treatment of Inflammatory Lung Diseases', Nanomedicine, vol. 17, no. 30, pp. 2209-2213.
View/Download from: Publisher's site
Bisht, A, Hemrajani, C, Rathore, C, Dhiman, T, Rolta, R, Upadhyay, N, Nidhi, P, Gupta, G, Dua, K, Chellappan, DK, Dev, K, Sourirajan, A, Chakraborty, A, Aljabali, AAA, Bakshi, HA, Negi, P & Tambuwala, MM 2022, 'Hydrogel composite containing azelaic acid and tea tree essential oil as a therapeutic strategy for Propionibacterium and testosterone-induced acne', Drug Delivery and Translational Research, vol. 12, no. 10, pp. 2501-2517.
View/Download from: Publisher's site
View description>>
AbstractAzelaic acid (AzA) is a USFDA bioactive prescribed againstacne vulgaris. It possesses delivery challenges like poor aqueous solubility, low skin-penetrability, and dose-dependent side effects, which could be overcome by its synergistic combination with tea tree oil (TTO) as a microemulsion (ME)-based hydrogel composite. AzA-TTO ME was prepared to employ pseudo-ternary phase diagram construction. The best AzA-TTO ME was of uniform size (polydispersity index < 0.7), nano-range (~357.4 ± 2% nm), transmittance (> 90%), and negative zeta potential (−1.42 ± 0.25% mV) values. ME hydrogel composite with optimum rheological and textural attributes showed better permeation, retention, and skin-compliant characteristics, vis-a-vis marketed formulation (Aziderm™) when evaluated in Wistar rat skin. In vitro antibacterial efficacy in bacterial strains, i.e.,Staphylococcus aureus,Propionibacterium acne, andStaphylococcus epidermidis, was evaluated employing agar well plate diffusion and broth dilution assay. ME hydrogel has shown an increase in zone of inhibition by two folds and a decrease in minimum inhibitory concentration (MIC) by eightfold againstP. acnesvis-a-vis AzA. Finally, ME hydrogel composite exhibited a better reduction in the papule density (93.75 ± 1.64%) in comparison to Aziderm™ 72.69 ± 4.67%) on acne as developed in rats by inducing testosterone. Thus, the developed AzA-TTO ME hydrogel composite promises an efficacious and comparatively safer drug delivery system for the topical therapy ofacne vulgaris.Graphical abstract
Bisht, A, Hemrajani, C, Upadhyay, N, Nidhi, P, Rolta, R, Rathore, C, Gupta, G, Dua, K, Chellappan, DK, Dev, K, Sourirajan, A, Aljabali, AAA, Bakshi, HA, Negi, P & Tambuwala, MM 2022, 'Azelaic Acid and Melaleuca Alternifolia Essential Oil co-loaded Vesicular Carrier for Combinational Therapy of Acne', Therapeutic Delivery, vol. 13, no. 1, pp. 13-29.
View/Download from: Publisher's site
View description>>
Aim: Azelaic acid (AzA), a comedolytic, antibacterial, anti-inflammatory anti-melanogenic agent, prescribed against acne vulgaris is safe on skin. Its combination with another widely used anti-acne agent, tea tree oil (EO) whose delivery is limited by volatility, instability and lipophilicity constraints was attempted. Method: Solvent injection was used to prepare AzA-EO integrated ethosomes. Result: Ethosomes were transformed into carbopol hydrogel, which exhibited pseudo-plastic properties with appreciable firmness, work of shear, stickiness and work of adhesion. The hydrogel showed better permeation and retention characteristics vis-a-vis commercial formulation (AzidermTM), when evaluated in Wistar rat skin. Further, ethosome hydrogel composite was better tolerated with no side effects. Conclusion: The findings suggests that the aforementioned strategy could be a potential treatment used for acne management.
Chan, Y, Singh, SK, Gulati, M, Wadhwa, S, Prasher, P, Kumar, D, Kumar, AP, Gupta, G, Kuppusamy, G, Haghi, M, George Oliver, BG, Adams, J, Chellappan, DK & Dua, K 2022, 'Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases', Journal of Drug Delivery Science and Technology, vol. 74, pp. 103541-103541.
View/Download from: Publisher's site
View description>>
Chronic lung diseases such as asthma, chronic obstructive pulmonary disease, lung cancer, and the recently emerged COVID-19, are a huge threat to human health, and among the leading causes of global morbidity and mortality every year. Despite availability of various conventional therapeutics, many patients remain poorly controlled and have a poor quality of life. Furthermore, the treatment and diagnosis of these diseases are becoming increasingly challenging. In the recent years, the application of nanomedicine has become increasingly popular as a novel strategy for diagnosis, treatment, prevention, as well as follow-up of chronic lung diseases. This is attributed to the ability of nanoscale drug carriers to achieve targeted delivery of therapeutic moieties with specificity to diseased site within the lung, thereby enhancing therapeutic outcomes of conventional therapies whilst minimizing the risks of adverse reactions. For this instance, monoolein is a polar lipid nanomaterial best known for its versatility, thermodynamic stability, biocompatibility, and biodegradability. As such, it is commonly employed in liquid crystalline systems for various drug delivery applications. In this review, we present the applications of monoolein as a novel nanomaterial-based strategy for targeted drug delivery with the potential to revolutionize therapeutic approaches in chronic lung diseases.
Charbe, NB, Castillo, F, Tambuwala, MM, Prasher, P, Chellappan, DK, Carreño, A, Satija, S, Singh, SK, Gulati, M, Dua, K, González-Aramundiz, JV & Zacconi, FC 2022, 'A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers', Blood Reviews, vol. 54, pp. 100927-100927.
View/Download from: Publisher's site
Chaudhary, A, Tomar, R, Mohammed B, S, Imran, M, I. Alaqel, S, S. Alamri, A, F. Alsanie, W, Alhomrani, M, Kumar Aror, M, Bisht, D, Dua, K, Kamal Kant, R, Singh, S, Nayeem, N & ., A 2022, 'In silico Screening of Phytochemicals as Potential Inhibitors of SARS-CoV-2 Mpro and Human ACE-2', International Journal of Pharmacology, vol. 18, no. 1, pp. 104-115.
View/Download from: Publisher's site
Chaudhary, B, Kumar, P, Arya, P, Singla, D, Kumar, V, Kumar, D, S, R, Wadhwa, S, Gulati, M, Singh, SK, Dua, K, Gupta, G & Gupta, MM 2022, 'Recent Developments in the Study of the Microenvironment of Cancer and DrugDelivery', Current Drug Metabolism, vol. 23, no. 13, pp. 1027-1053.
View/Download from: Publisher's site
View description>>
Abstract:Cancer is characterized by disrupted molecular variables caused by cells that deviate from regular signal transduction. The uncontrolled segment of such cancerous cells annihilates most of the tissues that contact them. Gene therapy, immunotherapy, and nanotechnology advancements have resulted in novel strategies for anticancer drug delivery. Furthermore, diverse dispersion of nanoparticles in normal stroma cells adversely affects the healthy cells and disrupts the crosstalk of tumour stroma. It can contribute to cancer cell progression inhibition and, conversely, to acquired resistance, enabling cancer cell metastasis and proliferation. The tumour's microenvironment is critical in controlling the dispersion and physiological activities of nano-chemotherapeutics which is one of the targeted drug therapy. As it is one of the methods of treating cancer that involves the use of medications or other substances to specifically target and kill off certain subsets of malignant cells. A targeted therapy may be administered alone or in addition to more conventional methods of care like surgery, chemotherapy, or radiation treatment. The tumour microenvironment, stromatogenesis, barriers and advancement in the drug delivery system across tumour tissue are summarised in this review.
Chellappan, DK, Paudel, KR, Tan, NW, Cheong, KS, Khoo, SSQ, Seow, SM, Chellian, J, Candasamy, M, Patel, VK, Arora, P, Singh, PK, Singh, SK, Gupta, G, Oliver, BG, Hansbro, PM & Dua, K 2022, 'Targeting the mitochondria in chronic respiratory diseases', Mitochondrion, vol. 67, pp. 15-37.
View/Download from: Publisher's site
Chellappan, DK, Prasher, P, Shukla, SD, Yee, TW, Kah, TK, Xyan, TW, Kid, TW, Si, TH, Weng, TS, Molugulu, N, Sakthivel, LP, Chellian, J, Madheswaran, T, Malipeddi, H, Singh, Y, Dureja, H, Kapoor, DN, Negi, P, Goyal, R, Thangavelu, L, Kumar, D, Gupta, PK, Jha, NK, Shastri, MD, MacLoughlin, R, Singh, SK, Gulati, M, Gupta, G & Dua, K 2022, 'Exploring the role of antibiotics and steroids in managing respiratory diseases', Journal of Biochemical and Molecular Toxicology, vol. 36, no. 10.
View/Download from: Publisher's site
View description>>
AbstractRespiratory diseases (RDs), such as chronic obstructive pulmonary disease, cystic fibrosis, asthma, and pneumonia, are associated with significant morbidity and mortality. Treatment usually consists of antibiotics and steroids. Relevant published literature reviews, studies, and clinical trials were accessed from institutional and electronic databases. The keywords used were respiratory diseases, steroids, antibiotics, and combination of steroids and antibiotics. Selected articles and literature were carefully reviewed. Antibiotics are often prescribed as the standard therapy to manage RDs. Types of causative respiratory pathogens, spectrum of antibiotics activity, route of administration, and course of therapy determine the type of antibiotics that are prescribed. Despite being associated with good clinical outcome, treatment failure and recurrence rate are still high. In addition, antibiotic resistance has been widely reported due to bacterial mutations in response to the use of antibiotics, which render them ineffective. Nevertheless, there has been a growing demand for corticosteroids (CS) and antibiotics to treat a wide variety of diseases, including various airway diseases, due to their immunosuppressive and anti‐inflammatory properties. The use of CS is well established and there are different formulations based on the diseases, such as topical administration, tablets, intravenous injections, and inhaled preparations. Both antibiotics and CS possess similar properties in terms of their anti‐inflammatory effects, especially regulating cytokine release. Thus, the current review examines and discusses the different applications of antibiotics, CS, and their combination in managing various RDs. Drawbacks of these interventions are also discussed.
Cochran, BJ, Manandhar, B & Rye, K-A 2022, 'HDL and Diabetes', pp. 119-127.
View/Download from: Publisher's site
Corrie, L, Gulati, M, Awasthi, A, Vishwas, S, Kaur, J, Khursheed, R, Kumar, R, Kumar, A, Imran, M, Chellappan, DK, Gupta, G, de Jesus Andreoli Pinto, T, Morris, A, Choonara, YE, Adams, J, Dua, K & Singh, SK 2022, 'Polysaccharide, fecal microbiota, and curcumin-based novel oral colon-targeted solid self-nanoemulsifying delivery system: formulation, characterization, and in-vitro anticancer evaluation', Materials Today Chemistry, vol. 26, pp. 101165-101165.
View/Download from: Publisher's site
Corrie, L, Gulati, M, Awasthi, A, Vishwas, S, Kaur, J, Khursheed, R, Porwal, O, Alam, A, Parveen, SR, Singh, H, Chellappan, DK, Gupta, G, Kumbhar, P, Disouza, J, Patravale, V, Adams, J, Dua, K & Singh, SK 2022, 'Harnessing the dual role of polysaccharides in treating gastrointestinal diseases: As therapeutics and polymers for drug delivery', Chemico-Biological Interactions, vol. 368, pp. 110238-110238.
View/Download from: Publisher's site
Costantino, AR, Charbe, N, Duarte, Y, Gutiérrez, M, Giordano, A, Prasher, P, Dua, K, Mandolesi, S & Zacconi, FC 2022, 'Toward the cholinesterase inhibition potential of TADDOL derivatives: Seminal biological and computational studies', Archiv der Pharmazie, vol. 355, no. 11, pp. 2200142-2200142.
View/Download from: Publisher's site
View description>>
AbstractAlzheimer's disease (AD) is a degenerative neurological disease characterized by gradual loss of cognitive skills and memory. The exact pathogenesis involved still remains unrevealed, but several studies indicate the involvement of an array of different enzymes, underlining the multifactorial character of the disease. Inhibition of these enzymes is therefore a powerful approach in the development of AD treatments, with promising candidates, including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidase. Interestingly, AChE is the target of a major pesticide family (organophosphates), with several reports indicating an intersection between the pesticide's activity and AD. In this study, various TADDOL derivatives were synthesized and their in vitro activities as AChE/BuChE inhibitors as well as their antioxidant activities were studied. Molecular modeling studies revealed the capability of TADDOL derivatives to bind to AChE and induce inhibition, especially compounds 2b and 3c furnishing IC50 values of 36.78 ± 8.97 and 59.23 ± 5.31 µM, respectively. Experimental biological activities and molecular modeling studies clearly demonstrate that TADDOL derivatives with specific stereochemistry have an interesting potential for the design of potent AChE inhibitors. The encouraging results for compounds 2b and 3c indicate them as promising scaffolds for selective and potent AChE inhibitors.
Dahiya, M, Awasthi, R, Gupta, G, Singh, SK, Gulati, M, Jha, NK, Jha, SK, Sharma, A, Prasher, P, Anand, K, Chellappan, DK, Dua, K & Dureja, H 2022, 'Optimization Studies on Imatinib Mesylate Loaded Nanoliposomes Using Box-Behnken Design', Nano Biomedicine and Engineering, vol. 14, no. 1, pp. 23-37.
View/Download from: Publisher's site
View description>>
Nanoliposomes are bilayer phospholipid vesicles used to encapsulate and deliver therapeutic agents. The study was aimed to investigate the effects of critical variables on nanoliposomes characteristics. Imatinib mesylate-loaded nanoliposomes were formulated by the two-step emulsification process using a high-speed homogenizer system and probe-type ultrasonicator. The Box-Behnken design was utilized to optimize the process parameters. The mean particle size of nanoliposomes was found to be 211 nm to 623.3 nm with a low value of polydispersity index (0.005 to 0.7). Zeta potential values varied from -27.6 mV to -9.2 mV in uncoated nanoliposomes to +27.5 mV in chitosancoated nanoliposomes. The encapsulation efficiency in formulation NLP-H8 containing 200 mg of phosphatidylcholine, homogenization speed of 12000 rpm, and 7 min of sonication time was found to be 76.49% without the coating and 85.4% in 0.2% w/v chitosan-coated nanoliposomes. TEM image confirmed the spherical shape of nanoliposomes. In-vitro drug release study demonstrated that the optimized nanoliposomal formulations released 84.67% of the loaded drug after 24 h in 0.1 N HCl. The IC50 value of formulation NLP-H8 was found to be 7.98 μM. Nanoliposomal formulations were prepared successfully with suitable size, morphology, encapsulation efficiency, and drug release. The models developed in this study may be utilized further as a response surface for the various parameters of nanoliposomes.
Darmarajan, T, Paudel, KR, Candasamy, M, Chellian, J, Madheswaran, T, Sakthivel, LP, Goh, BH, Gupta, PK, Jha, NK, Devkota, HP, Gupta, G, Gulati, M, Singh, SK, Hansbro, PM, Oliver, BGG, Dua, K & Chellappan, DK 2022, 'Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation', Environmental Science and Pollution Research, vol. 29, no. 36, pp. 54072-54087.
View/Download from: Publisher's site
Das, SS, Singh, SK, Verma, PRP, Jha, NK, Gupta, PK & Dua, K 2022, 'Mitigating Inflammation Using Advanced Drug Delivery By Targeting TNF-α in Lung Diseases', Future Medicinal Chemistry, vol. 14, no. 2, pp. 57-60.
View/Download from: Publisher's site
Dhanasekaran, M, M. Nadar, R, McDonald, K, Deruiter, J, Pathak, S, Ramesh, S, Vijayarani, R, Gopal, K, Babu Ramapuram, J, Dua, K, Moore, T, Ren, J & Dhanasekaran, M 2022, 'A Re-Evaluation of Past to Present-Day Use of the Blissful Neuronal Nutraceutical “Cannabis”', Journal of Food Nutrition and Metabolism, pp. 1-9.
View/Download from: Publisher's site
View description>>
The chronological events associated with cannabis utilization are viewed perceptively as matters/issues that happened from the period “before Christ” (BC) or “anno domini” (AD, “in the year of our Lord”) to the present time. Cannabis is one of the oldest natural products known to humanity worldwide and has been used by various civilizations, cultures, and religions before the birth of Christ. Interestingly, it is used to date and has the potential for future usage for centuries to come. Currently, the major religions around the world are Christianity, Islamism, Hinduism, Buddhism, Sikhism, Taoism, Judaism, Confucianism, Bahá'í, Shinto, Jainism, and Zoroastrianism, with their precepts regarding the use of cannabis products. Similarly, the most noted ancient civilizations, including the Incan Civilization, Aztec Civilization, Roman Civilization, Ancient Greek Civilization, Chinese Civilization, Mayan Civilization, Ancient Egyptian Civilization, Indus Valley Civilization, and Mesopotamian Civilization, have reported cannabis use. This review discusses cannabis in various civilizations and religions from the past to the present day.
Dhanjal, DS, Sharma, P, Mehta, M, Tambuwala, MM, Prasher, P, Paudel, KR, Liu, G, Shukla, SD, Hansbro, PM, Chellappan, DK, Dua, K & Satija, S 2022, 'Concepts of Advanced Therapeutic Delivery Systems for the Management of Remodeling and Inflammation in Airway Diseases', Future Medicinal Chemistry, vol. 14, no. 4, pp. 271-288.
View/Download from: Publisher's site
View description>>
Chronic respiratory disorders affect millions of people worldwide. Pathophysiological changes to the normal airway wall structure, including changes in the composition and organization of its cellular and molecular constituents, are referred to as airway remodeling. The inadequacy of effective treatment strategies and scarcity of novel therapies available for the treatment and management of chronic respiratory diseases have given rise to a serious impediment in the clinical management of such diseases. The progress made in advanced drug delivery, has offered additional advantages to fight against the emerging complications of airway remodeling. This review aims to address the gaps in current knowledge about airway remodeling, the relationships between remodeling, inflammation, clinical phenotypes and the significance of using novel drug delivery methods.
Dua, K, Lobenberg, R & Chellappan, DK 2022, 'Special Focus Issue on Targeted Drug Delivery for Inflammatory Lung Diseases', Nanomedicine, vol. 17, no. 12, pp. 813-815.
View/Download from: Publisher's site
Fernández, MEC, Zarzuelo, MJ, Fernández, NA, Valverde-Merino, MI & Martínez, FM 2022, 'Intervention model for detection, prevention and control of COVID-19 in community pharmacy', Brazilian Journal of Pharmaceutical Sciences, vol. 58.
View/Download from: Publisher's site
Field, MA, Yadav, S, Dudchenko, O, Esvaran, M, Rosen, BD, Skvortsova, K, Edwards, RJ, Keilwagen, J, Cochran, BJ, Manandhar, B, Bustamante, S, Rasmussen, JA, Melvin, RG, Chernoff, B, Omer, A, Colaric, Z, Chan, EKF, Minoche, AE, Smith, TPL, Gilbert, MTP, Bogdanovic, O, Zammit, RA, Thomas, T, Aiden, EL & Ballard, JWO 2022, 'The Australian dingo is an early offshoot of modern breed dogs', Science Advances, vol. 8, no. 16, pp. 1-14.
View/Download from: Publisher's site
View description>>
Dogs are uniquely associated with human dispersal and bring transformational insight into the domestication process. Dingoes represent an intriguing case within canine evolution being geographically isolated for thousands of years. Here, we present a high-quality de novo assembly of a pure dingo (CanFam_DDS). We identified large chromosomal differences relative to the current dog reference (CanFam3.1) and confirmed no expanded pancreatic amylase gene as found in breed dogs. Phylogenetic analyses using variant pairwise matrices show that the dingo is distinct from five breed dogs with 100% bootstrap support when using Greenland wolf as the outgroup. Functionally, we observe differences in methylation patterns between the dingo and German shepherd dog genomes and differences in serum biochemistry and microbiome makeup. Our results suggest that distinct demographic and environmental conditions have shaped the dingo genome. In contrast, artificial human selection has likely shaped the genomes of domestic breed dogs after divergence from the dingo.
Garg, U, Jain, N, Kaul, S, Rai, VK, Pandey, M, Nagaich, U & Dua, K 2022, 'The emerging role of 3D-printing in ocular drug delivery: Challenges, current status, and future prospects', Journal of Drug Delivery Science and Technology, vol. 76, pp. 103798-103798.
View/Download from: Publisher's site
Hemrajani, C, Negi, P, Parashar, A, Gupta, G, Jha, NK, Singh, SK, Chellappan, DK & Dua, K 2022, 'Overcoming drug delivery barriers and challenges in topical therapy of atopic dermatitis: A nanotechnological perspective', Biomedicine & Pharmacotherapy, vol. 147, pp. 112633-112633.
View/Download from: Publisher's site
View description>>
Atopic dermatitis (AD) is an inflammatory disorder centered around loss of epidermal barrier function, and T helper 2 (Th2) immune responses. The current understanding of disease heterogeneity and complexity, limits the rational use of existing topical, systemic therapeutic agents, but paves way for development of advanced therapeutic agents. Additionally, advanced nanocarriers that deliver therapeutics to target cells, seem to offer a promising strategy, to overcome intrinsic limitations and challenges of conventional, and traditional drug delivery systems. Ever-evolving understanding of molecular target sites and complex pathophysiology, adverse effects of current therapeutic options, inefficient disease recapitulation by existing animal models are some of the challenges that we face. Also, despite limited success in market translatibility, nanocarriers have demonstrated excellent preclinical results and have been extensively studied for AD. Detailed research on behavior of nanocarriers in different patients and tailored therapy to account for phenotypic variability of the disease are the new research avenues that we look forward to.
Imran, M, Paudel, KR, Jha, SK, Hansbro, PM, Dua, K & Mohammed, Y 2022, 'Dressing Multifunctional Nanoparticles with Natural Cell-Derived Membranes for Superior Chemotherapy', Nanomedicine, vol. 17, no. 10, pp. 665-670.
View/Download from: Publisher's site
Jain, N, Pandey, M, Sharma, P, Gupta, G, Gorain, B & Dua, K 2022, 'Recent developments in plant‐derived edible nanoparticles as therapeutic nanomedicines', Journal of Food Biochemistry, vol. 46, no. 12, p. e14479.
View/Download from: Publisher's site
View description>>
The use of nanotechnology in the treatment of numerous disorders has proven effective. The predicted development of plant-derived edible nanoparticles (PDNPs) as potential therapeutic agents for treating illness or in the delivery of drugs is inevitable. PDNPs generated from plants resemble mammal-extracted exosomes structurally. In contrast to their excellent biocompatibility with healthy cells, PDNPs are skewed toward malignancies by selectively targeting those cells via unique endocytic pathways. They can be generated in large quantities, are nontoxic, and have tissue-specific targeting abilities. Thus, with fewer off-target effects, using these PDNPs could broaden the breadth of pharmacological therapy. In this discussion, we emphasize the properties and biological activities of PDNPs isolated from fruits and vegetables and discuss the promising implications of these particles as nanomedicines. PRACTICAL APPLICATIONS: PDNPs have reportedly been employed for therapeutic applications for several ailments and are believed to have characteristics in common with exosomes generated from mammals. The advantages of PDNPs over mammalian-derived exosomes are numerous. Firstly, they may be produced on a commercial scale using a variety of efficient renewable sources. Secondly, the PDNPs' natural components developed in plant cells promise improved cytocompatibility, tolerability, low cytotoxicity, or other adverse effects. We evaluated some current studies on the applications and potential of PDNPs in this article. PDNPs could create new opportunities for drug discovery because of recent advancements in medicine and drug delivery system nanotechnology. Unfortunately, the precise mechanisms behind PDNP's functions and interaction in pathogenic processes have not yet been completely elucidated; as a result, the potential consequences of their clinical use are uncertain. Overall, PDNPs show a wide range of therapeutic possibilities that may be advantageous to pat...
Jangra, A, Verma, M, Kumar, D, Chandrika, Rachamalla, M, Dey, A, Dua, K, Jha, SK, Ojha, S, Alexiou, A, Kumar, D & Jha, NK 2022, 'Targeting endoplasmic reticulum stress using natural products in neurological disorders', Neuroscience & Biobehavioral Reviews, vol. 141, pp. 104818-104818.
View/Download from: Publisher's site
Jena, R, Vishwas, S, Kumar, R, Kaur, J, Khursheed, R, Gulati, M, Singh, TG, Vanathi, BM, Alam, A, Kumar, B, Chaitanya, MVNL, Gupta, S, Negi, P, Pandey, NK, Bhatt, S, Gupta, G, Chellappan, DK, Oliver, BG, Dua, K & Singh, SK 2022, 'Treatment strategies for HIV infection with emphasis on role of CRISPR/Cas9 gene: Success so far and road ahead', European Journal of Pharmacology, vol. 931, pp. 175173-175173.
View/Download from: Publisher's site
View description>>
Advances in biotechnology have led to improving human health with number of novel approaches to mitigate life-threatening diseases such as human immunodeficiency virus (HIV) infection, cancer, and neurodegenerative diseases. In the case of HIV, the damage caused by the retrovirus to the immune system leads to opportunistic infection as well as an elevated risk of autoimmune disease and cancer. Furthermore, clinical symptoms associated with the virus itself may arise. Antiretroviral drug therapy using reverse transcriptase inhibitors, protease inhibitors, fusion inhibitor, chemokine receptor 5 antagonist and integrase strand transfer inhibitors have shown promising results in treating HIV infection and available in market in the form of various dosage forms. However, they are unable to completely cure the disease because of complexity in pathogenesis of HIV. In addition, these drugs have some limitations of poor solubility, permeability or, poor receptor binding capacity. To overcome these drawbacks, many novel drug delivery systems for the drugs belonging to above mentioned categories have been developed. The possibility of treating HIV infection using CRISPR-Cas9 gene editing has been found in 2015. This provided a new area of research to the scientists who are working towards alternative treatment strategies for HIV infections. The present article describes about various treatment strategies used to treat HIV infections with special emphasis on the role of CRISPR/Cas9 gene-based technology. The potential benefits of specific epigenetic modification in the c-c chemokine receptor 5 gene (CCR5) via various delivery methods are also highlighted.
Jha, NK, Arfin, S, Jha, SK, Kar, R, Dey, A, Gundamaraju, R, Ashraf, GM, Gupta, PK, Dhanasekaran, S, Abomughaid, MM, Das, SS, Singh, SK, Dua, K, Roychoudhury, S, Kumar, D, Ruokolainen, J, Ojha, S & Kesari, KK 2022, 'Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling', Seminars in Cancer Biology, vol. 86, pp. 1086-1104.
View/Download from: Publisher's site
View description>>
Recent mounting evidence has revealed extensive genetic heterogeneity within tumors that drive phenotypic variation affecting key cancer pathways, making cancer treatment extremely challenging. Diverse cancer types display resistance to treatment and show patterns of relapse following therapy. Therefore, efforts are required to address tumor heterogeneity by developing a broad-spectrum therapeutic approach that combines targeted therapies. Inflammation has been progressively documented as a vital factor in tumor advancement and has consequences in epigenetic variations that support tumor instigation, encouraging all the tumorigenesis phases. Increased DNA damage, disrupted DNA repair mechanisms, cellular proliferation, apoptosis, angiogenesis, and its incursion are a few pro-cancerous outcomes of chronic inflammation. A clear understanding of the cellular and molecular signaling mechanisms of tumor-endorsing inflammation is necessary for further expansion of anti-cancer therapeutics targeting the crosstalk between tumor development and inflammatory processes. Multiple inflammatory signaling pathways, such as the NF-κB signaling pathway, JAK-STAT signaling pathway, MAPK signaling, PI3K/AKT/mTOR signaling, Wnt signaling cascade, and TGF-β/Smad signaling, have been found to regulate inflammation, which can be modulated using various factors such as small molecule inhibitors, phytochemicals, recombinant cytokines, and nanoparticles in conjugation to phytochemicals to treat cancer. Researchers have identified multiple targets to specifically alter inflammation in cancer therapy to restrict malignant progression and improve the efficacy of cancer therapy. siRNA-and shRNA-loaded nanoparticles have been observed to downregulate STAT3 signaling pathways and have been employed in studies to target tumor malignancies. This review highlights the pathways involved in the interaction between tumor advancement and inflammatory progression, along with the novel approac...
Jha, NK, Chen, W-C, Kumar, S, Dubey, R, Tsai, L-W, Kar, R, Jha, SK, Gupta, PK, Sharma, A, Gundamaraju, R, Pant, K, Mani, S, Singh, SK, Maccioni, RB, Datta, T, Singh, SK, Gupta, G, Prasher, P, Dua, K, Dey, A, Sharma, C, Mughal, YH, Ruokolainen, J, Kesari, KK & Ojha, S 2022, 'Molecular mechanisms of developmental pathways in neurological disorders: a pharmacological and therapeutic review', Open Biology, vol. 12, no. 3.
View/Download from: Publisher's site
View description>>
Developmental signalling pathways such as Wnt/β-catenin, Notch and Sonic hedgehog play a central role in nearly all the stages of neuronal development. The term ‘embryonic’ might appear to be a misnomer to several people because these pathways are functional during the early stages of embryonic development and adulthood, albeit to a certain degree. Therefore, any aberration in these pathways or their associated components may contribute towards a detrimental outcome in the form of neurological disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and stroke. In the last decade, researchers have extensively studied these pathways to decipher disease-related interactions, which can be used as therapeutic targets to improve outcomes in patients with neurological abnormalities. However, a lot remains to be understood in this domain. Nevertheless, there is strong evidence supporting the fact that embryonic signalling is indeed a crucial mechanism as is manifested by its role in driving memory loss, motor impairments and many other processes after brain trauma. In this review, we explore the key roles of three embryonic pathways in modulating a range of homeostatic processes such as maintaining blood–brain barrier integrity, mitochondrial dynamics and neuroinflammation. In addition, we extensively investigated the effect of these pathways in driving the pathophysiology of a range of disorders such as Alzheimer's, Parkinson's and diabetic neuropathy. The concluding section of the review is dedicated to neurotherapeutics, wherein we identify and list a range of biological molecules and compounds that have shown enormous potential in improving prognosis in patients with these disorders.
Jha, SK, Imran, M, Paudel, KR, Mohammed, Y, Hansbro, P & Dua, K 2022, 'Treating Primary Lymphoma of The Brain in AIDS Patients Via Multifunctional Oral Nanoparticulate Systems', Nanomedicine, vol. 17, no. 7, pp. 425-429.
View/Download from: Publisher's site
K, A, Sharma, A, Kumar, D, Singh, SK, Gupta, G, Chellappan, DK, Dua, K & Nagraik, R 2022, 'Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review', Journal of Medical Virology, vol. 94, no. 10, pp. 4628-4643.
View/Download from: Publisher's site
View description>>
AbstractThe global pandemic of COVID‐19 began in December 2019 and is still continuing. The past 2 years have seen the emergence of several variants that were more vicious than each other. The emergence of Omicron (B.1.1.529) proved to be a huge epidemiological concern as the rate of infection of this particular strain was enormous. The strain was identified in South Africa on November 24, 2021 and was classified as a “Variant of Concern” on November 26, 2021. The Omicron variant possessed mutations in the key RBD region, the S region, thereby increasing the affinity of ACE2 for better transmission of the virus. Antibody resistance was found in this variant and it was able to reduce vaccine efficiency of vaccines. The need for a booster vaccine was brought forth due to the prevalence of the Omicron variant and, subsequently, this led to targeted research and development of variant‐specific vaccines and booster dosage. This review discusses broadly the genomic characters and features of Omicron along with its specific mutations, evolution, antibody resistance, and evasion, utilization of CRISPR‐Cas12a assay for Omicron detection, T‐cell immunity elicited by vaccines against Omicron, and strategies to decrease Omicron infection along with COVID‐19 and it also discusses on XE recombinant variant and on infectivity of BA.2 subvariant of Omicron.
Kadukkattil Ramanunny, A, Singh, SK, Wadhwa, S, Gulati, M, Kapoor, B, Khursheed, R, Kuppusamy, G, Dua, K, Dureja, H, Chellappan, DK, Jha, NK, Gupta, PK & Vishwas, S 2022, 'Overcoming hydrolytic degradation challenges in topical delivery: non-aqueous nano-emulsions', Expert Opinion on Drug Delivery, vol. 19, no. 1, pp. 23-45.
View/Download from: Publisher's site
View description>>
Introduction
Non-aqueous nano-emulsions (NANEs) are colloidal lipid-based dispersions with nano-sized droplets formed by mixing two immiscible phases, none of which happens to be an aqueous phase. Their ability to incorporate water and oxygen sensitive drugs without any susceptibility to degradation makes them the optimum dosage form for such candidates. In NANEs, polar liquids or polyols replace the aqueous phase while surfactants remain same as used in conventional emulsions. They are a part of the nano-emulsion family albeit with substantial difference in composition and application.
Areas covered
The present review provides a brief insight into the strategies of loading water-sensitive drugs into NANEs. Further advancement in these anhydrous systems with the use of solid particulate surfactants in the form of Pickering emulsions is also discussed.
Expert opinion
NANEs offer a unique platform for delivering water-sensitive drugs by loading them in anhydrous formulation. The biggest advantage of NANEs vis-à-vis the other nano-cargos is that they can also be prepared without using equipment-intensive techniques. However, the use of NANEs in drug delivery is quite limited. Looking at the small number of studies available in this direction, a need for further research in this field is required to explore this delivery system further.
Kapoor, B, Singh, A, Gulati, M, Singh, SK, Rani, P, Alzahrani, Q, Dua, K, Dureja, H & Corrie, L 2022, 'Orchestration of Obesolytic Activity of Microbiome: Metabiotics at Centre Stage', Current Drug Metabolism, vol. 23, no. 2, pp. 90-98.
View/Download from: Publisher's site
View description>>
Abstract:Metabiotics have emerged as the safer alternatives to probiotics in last decade. Unlike probiotics that arelive microbes, metabiotics are the low molecular weight bioactive metabolites produced by the gut microbiota. Whileoffering a similar profile of health benefits as that of probiotics, metabiotics are free from the risks and uncertainresponses associated with administration of live bacteria into the body. Metabiotics have demonstrated substantialeffectiveness across the ethnicities, age, gender and nutritional habits in a number of metabolic disorders, includingobesity. Obesity is attributed to the offsetting of the energy homeostasis of the body due to a number of genetic,endocrinological, and environmental factors leading to obesity. The obesogenic mechanisms are quite complicated asthey result from a complex interplay among a number of factors. Owing to a variety of constituents exerting theiraction through different pathways, metabiotics offer a pragmatic option for treatment as well as prevention of obesityby addressing heterogeneous aspects of its aetiology. In this review, we categorize various components of metabioticsand discuss their cross-talk with host cells at the molecular level. We also discuss the challenges in understandingthese interactions and their potential effects on obesity treatment and prevention strategies. Considering the alarmingrise in obesity all over the world, metabiotics offer an attractive non-pharmacological approach to spearhead thestrategies being designed to combat the challenges posed by the obesity epidemic.
Kaur, J, Gulati, M, Corrie, L, Awasthi, A, Jha, NK, Chellappan, DK, Gupta, G, MacLoughlin, R, Oliver, BG, Dua, K & Singh, SK 2022, 'Role of Nucleic Acid-Based Polymeric Micelles in Treating Lung Diseases', Nanomedicine, vol. 17, no. 25, pp. 1951-1960.
View/Download from: Publisher's site
View description>>
The prevalence of lung diseases is increasing year by year and existing drug therapies only provide symptomatic relief rather than targeting the actual cause. Nucleic acids can be used as an alternative therapeutic approach owing to their potential to reform a homeostatic balance by upregulating protective genes or downregulating damaging genes. However, their inherent properties, such as poor stability, ineffective cellular uptake, negative charge and so on, hinder their clinical utility. Such limitations can be overcome by exploiting the functional chemistry of polymeric micelles (PMs) for site-specific delivery, transfection efficiency and improved stability. With this objective, the present work describes the advancements made in designing nucleic acid-based PMs for treating lung diseases followed by approaches requiring consideration for clinical applications.
Kaur, J, Gulati, M, Famta, P, Corrie, L, Awasthi, A, Saini, S, Khatik, GL, Bettada, VG, Madhunapantula, SV, Paudel, KR, Gupta, G, Chellappan, DK, Arshad, MF, Adams, J, Gowthamarajan, K, Dua, K, Hansbro, PM & Singh, SK 2022, 'Polymeric micelles loaded with glyburide and vanillic acid: I. Formulation development, in-vitro characterization and bioavailability studies', International Journal of Pharmaceutics, vol. 624, pp. 121987-121987.
View/Download from: Publisher's site
Kaur, J, Gulati, M, Jha, NK, Disouza, J, Patravale, V, Dua, K & Singh, SK 2022, 'Recent advances in developing polymeric micelles for treating cancer: Breakthroughs and bottlenecks in their clinical translation', Drug Discovery Today, vol. 27, no. 5, pp. 1495-1512.
View/Download from: Publisher's site
View description>>
Polymeric micelles (PMs) have been explored pre-clinically for the delivery of chemotherapeutics to treat cancer. Their unique features, such as easy surface functionalization, stimuli-responsiveness, good stability, ability to modify drug release, enhanced permeation and retention effect, and potential to encapsulate more than one type of therapeutic molecules at a time, make them unique carriers for the targeted delivery or for enhancing the bioavailability of chemotherapeutics. PMs can also be used as theranostic nanocarriers for the mapping of drug therapy along with tumor imaging in patients with cancer. This review focuses on the limitations of existing treatment strategies and on innovative approaches employed for the functionalization of PMs for targeting cancer cells. In addition, the bottlenecks associated with the translation of PMs from the laboratory to clinics are also discussed.
Kaur, J, Gulati, M, Kapoor, B, Jha, NK, Gupta, PK, Gupta, G, Chellappan, DK, Devkota, HP, Prasher, P, Ansari, MS, Aba Alkhayl, FF, Arshad, MF, Morris, A, Choonara, YE, Adams, J, Dua, K & Singh, SK 2022, 'Advances in designing of polymeric micelles for biomedical application in brain related diseases', Chemico-Biological Interactions, vol. 361, pp. 109960-109960.
View/Download from: Publisher's site
View description>>
In recent years, unique physicochemical properties of amphiphilic block copolymers have been utilized to design the polymeric micelles for brain-specific delivery of drugs, proteins, peptides and genes. Their unique properties such as nano-size, charge-switching ability, stimuli-responsive cargo release, flexible structure, and self-assembly enable them to overcome limitations of conventional dosage forms that include rapid drug release, drug efflux, and poor brain bioavailability, and poor stability. These limitations hinder their therapeutic efficacy in treating brain diseases. Their ease of functionalization and enhanced penetration and retention effect make them suitable nanocarriers for the diagnosis of various brain diseases. In this context, the present manuscript provides an insight into the progress made in the functionalization of micelles such as the incorporation of stimuli-sensitive moieties in copolymers, conjugation of cargo molecules with the core-forming block via responsive smart linkers, and conjugation of active ligands and imaging moieties with the corona forming block for brain targeting and imaging. Further, the review also expounds on the role of polymeric micelles in delivering neurotherapeutic to the brain. Some patents related to polymeric micelles formulated for brain delivery are also enlisted.
Kaur, J, Gulati, M, Singh, SK, Kuppusamy, G, Kapoor, B, Mishra, V, Gupta, S, Arshad, MF, Porwal, O, Jha, NK, Chaitanya, MVNL, Chellappan, DK, Gupta, G, Gupta, PK, Dua, K, Khursheed, R, Awasthi, A & Corrie, L 2022, 'Discovering multifaceted role of vanillic acid beyond flavours: Nutraceutical and therapeutic potential', Trends in Food Science & Technology, vol. 122, pp. 187-200.
View/Download from: Publisher's site
Kaur, J, Gulati, M, Zacconi, F, Dureja, H, Loebenberg, R, Ansari, MS, AlOmeir, O, Alam, A, Chellappan, DK, Gupta, G, Jha, NK, Pinto, TDJA, Morris, A, Choonara, YE, Adams, J, Dua, K & Singh, SK 2022, 'Biomedical Applications of polymeric micelles in the treatment of diabetes mellitus: Current success and future approaches', Expert Opinion on Drug Delivery, vol. 19, no. 7, pp. 771-793.
View/Download from: Publisher's site
View description>>
INTRODUCTION: Diabetes mellitus (DM) is the most common metabolic disease and multifactorial, harming patients worldwide. Extensive research has been carried out in the search for novel drug delivery systems offering reliable control of glucose levels for diabetics, aiming at efficient management of DM. AREAS COVERED: Polymeric micelles (PMs) as smart drug delivery nanocarriers are discussed, focusing on oral drug delivery applications for the management of hyperglycaemia. The most recent approaches used for the preparation of smart PMs employ molecular features of amphiphilic block copolymers (ABCs), such as stimulus sensitivity, ligand conjugation, and as a more specific example the ability to inhibit islet amyloidosis. EXPERT OPINION: PMs provide a unique platform for self-regulated or spatiotemporal drug delivery, mimicking the working mode of pancreatic islets to maintain glucose homeostasis for prolonged periods. This unique characteristic is achieved by tailoring the functional chemistry of ABCs considering the physicochemical traits of PMs, including sensing capabilities, hydrophobicity etc. In addition, the application of ABCs for the inhibition of conformational changes in islet amyloid polypeptide garnered attention as one of the root causes of DM. However, research in this field is limited and further studies at the clinical level are required.
Khursheed, R, Dua, K, Vishwas, S, Gulati, M, Jha, NK, Aldhafeeri, GM, Alanazi, FG, Goh, BH, Gupta, G, Paudel, KR, Hansbro, PM, Chellappan, DK & Singh, SK 2022, 'Biomedical applications of metallic nanoparticles in cancer: Current status and future perspectives', Biomedicine & Pharmacotherapy, vol. 150, pp. 112951-112951.
View/Download from: Publisher's site
Khursheed, R, Gulati, M, Wadhwa, S, Vishwas, S, Sharma, DS, Corrie, L, Alam, A, Alnasser, SM, Aba Alkhayl, FF, Parveen, Z, Nammi, S, Chellappan, DK, Gupta, G, Zacconi, F, Steel, A, Adams, J, Jha, NK, Dua, K & Singh, SK 2022, 'Multifaceted role of synbiotics as nutraceuticals, therapeutics and carrier for drug delivery', Chemico-Biological Interactions, vol. 368, pp. 110223-110223.
View/Download from: Publisher's site
View description>>
Synbiotics, are a combination of probiotics and prebiotics. They play an important role in metabolizing different nutritional substrates and thus helps in the maintenance of human health. Any disbalance in the gut microflora, known as dysbiosis, is known to lead to a number of diseased conditions. It can be reverted by the administration of synbiotics. Present review highlights various mechanistic pathways through which synbiotics act as therapeutics. The dual role of synbiotics as nutraceutical and excipient in developing oral formulations are entailed with case studies. The findings entailed that there exist numerous studies on prebiotics as well as probiotics have been carried out to show their effects in several diseases. However, the concept of combining together them for prevention and treatment of various pathological conditions accruing from dysbiosis is relatively new. Synbiotics, however, face challenge of low stability during their sojourn in the GIT, which is generally overcome by various encapsulation techniques. Various studies also showed potential role of synbiotics in drug delivery. However, it is an emerging area and lacks clinical correlation. It is important to focus on clinical trials of formulations wherein synbiotics have been used as therapeutic moiety as well as pharmaceutical carrier for treating various diseases.
Khursheed, R, Paudel, KR, Gulati, M, Vishwas, S, Jha, NK, Hansbro, PM, Oliver, BG, Dua, K & Singh, SK 2022, 'Expanding The Arsenal Against Pulmonary Diseases Using Surface-Functionalized Polymeric Micelles: Breakthroughs and Bottlenecks', Nanomedicine, vol. 17, no. 12, pp. 881-911.
View/Download from: Publisher's site
View description>>
Pulmonary diseases such as lung cancer, asthma and tuberculosis have remained one of the common challenges globally. Polymeric micelles (PMs) have emerged as an effective technique for achieving targeted drug delivery for a local as well as a systemic effect. These PMs encapsulate and protect hydrophobic drugs, increase pulmonary targeting, decrease side effects and enhance drug efficacy through the inhalation route. In the current review, emphasis has been placed on the different barriers encountered by the drugs given via the pulmonary route and the mechanism of PMs in achieving drug targeting. The applications of PMs in different pulmonary diseases have also been discussed in detail.
Khursheed, R, Singh, SK, Kumar, B, Wadhwa, S, Gulati, M, A, A, Awasthi, A, Vishwas, S, Kaur, J, Corrie, L, K.R., A, Kumar, R, Jha, NK, Gupta, PK, Zacconi, F, Dua, K, Chitranshi, N, Mustafa, G & Kumar, A 2022, 'Self-nanoemulsifying composition containing curcumin, quercetin, Ganoderma lucidum extract powder and probiotics for effective treatment of type 2 diabetes mellitus in streptozotocin induced rats', International Journal of Pharmaceutics, vol. 612, pp. 121306-121306.
View/Download from: Publisher's site
View description>>
Liquid self-nanoemulsifying drug delivery system (L-SNEDDS) of curcumin and quercetin were prepared by dissolving them in isotropic mixture of Labrafil M1944CS®, Capmul MCM®, Tween-80® and Transcutol P®. The prepared L-SNEDDS were solidified using Ganoderma lucidum extract, probiotics and Aerosil-200® using spray drying. These were further converted into pellets using extrusion-spheronization. The mean droplet size and zeta potential of L-SNEDDS were found to be 63.46 ± 2.12 nm and - 14.8 ± 3.11 mV while for solid SNEDDS pellets, these were 72.46 ± 2.16 nm and -38.7 ± 1.34 mV, respectively. The dissolution rate for curcumin and quercetin each was enhanced by 4.5 folds while permeability was enhanced by 5.28 folds (curcumin) and 3.35 folds (quercetin) when loaded into SNEDDS pellets. The Cmax for curcumin and quercetin containing SNEDDS pellets was found 532.34 ± 5.64 ng/mL and 4280 ± 65.67 ng/mL, respectively. This was 17.55 and 3.48 folds higher as compared to their naïve forms. About 50.23- and 5.57-folds increase in bioavailability was observed for curcumin and quercetin respectively, upon loading into SNEDDS pellets. SNEDDS pellets were found stable at accelerated storage conditions. The developed formulation were able to normalize the levels of blood glucose, lipids, antioxidant biomarkers, and tissue architecture of pancreas and liver in streptozotocin induced diabetic rats as compared to their naïve forms.
Khursheed, R, Singh, SK, Wadhwa, S, Gulati, M, Jha, NK, Gupta, G, Devkota, HP, Prasher, P, Chellappan, DK & Dua, K 2022, 'A sojourn into therapeutic and nutraceutical potential of curcumin and its novel drug delivery system: Current achievements and future perspectives', South African Journal of Botany, vol. 149, pp. 944-962.
View/Download from: Publisher's site
Khursheed, R, Wadhwa, S, Kumar, B, Gulati, M, Gupta, S, Chaitanya, MVNL, Kumar, D, Jha, NK, Gupta, G, Prasher, P, Chellappan, DK, Dua, K & Singh, SK 2022, 'Development and validation of RP-HPLC based bioanalytical method for simultaneous estimation of curcumin and quercetin in rat's plasma', South African Journal of Botany, vol. 149, pp. 870-877.
View/Download from: Publisher's site
Krishnan, S, Kumar Narasimhan, A, Gangodkar, D, Dhanasekaran, S, Kumar Jha, N, Dua, K, Thakur, VK & Kumar Gupta, P 2022, 'Aptameric nanobiosensors for the diagnosis of COVID-19: An update', Materials Letters, vol. 308, pp. 131237-131237.
View/Download from: Publisher's site
Kumar, AP, Bilehal, D, Desalegn, T, Kumar, S, Ahmed, F, Murthy, HCA, Kumar, D, Gupta, G, Chellappan, DK, Singh, SK, Dua, K & Lee, Y-I 2022, 'Studies on Synthesis and Characterization of Fe3O4@SiO2@Ru Hybrid Magnetic Composites for Reusable Photocatalytic Application', Adsorption Science & Technology, vol. 2022, pp. 1-18.
View/Download from: Publisher's site
View description>>
Degradation of dye pollutants by the photocatalytic process has been regarded as the most efficient green method for removal organic dyes from contaminated water. The current research work describes the synthesis of Fe3O4@SiO2@Ru hybrid magnetic composites (HMCs) and their photocatalytic degradation of two azo dye pollutants, methyl orange (MO) and methyl red (MR), under irradiation of visible light. The synthesis of Fe3O4@SiO2@Ru HMCs involves three stages, including synthesis of Fe3O4 magnetic microspheres (MMSs), followed by silica (SiO2) coating to get Fe3O4@SiO2 MMSs, and then incorporation of presynthesized Ru nanoparticles (~3 nm) onto the surface of Fe3O4@SiO2 HMCs. The synthesized HMCs were characterized by XRD, FTIR, TEM, EDS, XPS, BET analysis, UV-DRS, PL spectroscopy, and VSM to study the physical and chemical properties. Furthermore, the narrow band gap energy of the HMC photocatalyst is a significant parameter that provides high photocatalytic properties due to the high light adsorption. The photocatalytic activity of synthesized Fe3O4@SiO2@Ru HMCs was assessed by researching their ability to degrade the aqueous solution of MO and MR dyes under visible radiation, and the influence of various functional parameters on photocatalytic degradation has also been studied. The results indicate that the photocatalytic degradation of MO and MR dyes is more than 90%, and acid media favors better degradation. The probable mechanism of photodegradation of azo dyes by Fe3O4@SiO2@Ru HMC catalysts has been propose...
Kumar, R, Kumar, R, Khurana, N, Singh, SK, Khurana, S, Verma, S, Sharma, N, Vyas, M, Dua, K, Khursheed, R, Awasthi, A & Vishwas, S 2022, 'Improved neuroprotective activity of Fisetin through SNEDDS in ameliorating the behavioral alterations produced in rotenone-induced Parkinson’s model', Environmental Science and Pollution Research, vol. 29, no. 33, pp. 50488-50499.
View/Download from: Publisher's site
Kumbhar, P, Kole, K, Khadake, V, Marale, P, Manjappa, A, Nadaf, S, Jadhav, R, Patil, A, Singh, SK, Dua, K, Jha, NK, Disouza, J & Patravale, V 2022, 'Nanoparticulate drugs and vaccines: Breakthroughs and bottlenecks of repurposing in breast cancer', Journal of Controlled Release, vol. 349, pp. 812-830.
View/Download from: Publisher's site
View description>>
Breast cancer (BC) is a highly diagnosed and topmost cause of death in females worldwide. Drug repurposing (DR) has shown great potential against BC by overcoming major shortcomings of approved anticancer therapeutics. However, poor physicochemical properties, pharmacokinetic performance, stability, non-selectivity to tumors, and side effects are severe hurdles in repurposed drug delivery against BC. The variety of nanocarriers (NCs) has shown great promise in delivering repurposed therapeutics for effective treatment of BC via improving solubility, stability, tumor selectivity and reducing toxicity. Besides, delivering repurposed cargos via theranostic NCs can be helpful in the quick diagnosis and treatment of BC. Localized delivery of repurposed candidates through apt NCs can diminish the systemic side effects and improve anti-tumor effectiveness. However, breast tumor variability and tumor microenvironment have created several challenges to nanoparticulate delivery of repurposed cargos. This review focuses on DR as an ingenious strategy to treat BC and circumvent the drawbacks of approved anticancer therapeutics. Various nanoparticulate avenues delivering repurposed therapeutics, including non-oncology cargos and vaccines to target BC effectively, are discussed along with case studies. Moreover, clinical trial information on repurposed medications and vaccines for the treatment of BC is covered along with various obstacles in nanoparticulate drug delivery against cancer that have been so far identified. In a nutshell, DR and drug delivery of repurposed drugs via NCs appears to be a propitious approach in devastating BC.
Kumbhar, P, Kole, K, Yadav, T, Bhavar, A, Waghmare, P, Bhokare, R, Manjappa, A, Jha, NK, Chellappan, DK, Shinde, S, Singh, SK, Dua, K, Salawi, A, Disouza, J & Patravale, V 2022, 'Drug repurposing: An emerging strategy in alleviating skin cancer', European Journal of Pharmacology, vol. 926, pp. 175031-175031.
View/Download from: Publisher's site
Kumbhar, P, Manjappa, A, Shah, R, Jha, NK, Singh, SK, Dua, K, Disouza, J & Patravale, V 2022, 'Inhalation delivery of repurposed drugs for lung cancer: Approaches, benefits and challenges', Journal of Controlled Release, vol. 341, pp. 1-15.
View/Download from: Publisher's site
Lambert, M, Smit, CCH, De Vos, S, Benko, R, Llor, C, Paget, WJ, Briant, K, Pont, L, Van Dijk, L & Taxis, K 2022, 'A systematic literature review and meta‐analysis of community pharmacist‐led interventions to optimise the use of antibiotics', British Journal of Clinical Pharmacology, vol. 88, no. 6, pp. 2617-2641.
View/Download from: Publisher's site
View description>>
AimsThe aim of this systematic review is to assess the effects of community pharmacist‐led interventions to optimise the use of antibiotics and identify which interventions are most effective.MethodsThis review was conducted according to the PRISMA guidelines (PROSPERO: CRD42020188552). PubMed, EMBASE and the Cochrane Central Register of Controlled Trials were searched for (randomised) controlled trials. Included interventions were required to target antibiotic use, be set in the community pharmacy context, and be pharmacist‐led. Primary outcomes were quality of antibiotic supply and adverse effects while secondary outcomes included patient‐reported outcomes. Risk of bias was assessed using the ‘Cochrane suggested risk of bias criteria’ and narrative synthesis of primary outcomes conducted.ResultsSeventeen studies were included covering in total 3822 patients (mean age 45.6 years, 61.9% female). Most studies used educational interventions. Three studies reported on primary outcomes, 12 on secondary outcomes and two on both. Three studies reported improvements in quality of dispensing, interventions led to more intensive symptom assessment (up to 30% more advice given) and a reduction of over‐the‐counter supply up to 53%. Three studies led to higher consumer satisfaction, effects on adherence from nine studies were mixed (risk difference 0.04 [−0.02, 0.10]). All studies had unclear or high risks of bias across at least one domain, with large heterogeneity between studies.ConclusionsOur review suggests some positive results from pharmacist‐led interventions, but the interventions do not seem sufficiently effective as currently implemented. This review should be interpreted as exploratory research, as more high‐quality research ...
Liu, G, Jarnicki, AG, Paudel, KR, Lu, W, Wadhwa, R, Philp, AM, Van Eeckhoutte, H, Marshall, JE, Malyla, V, Katsifis, A, Fricker, M, Hansbro, NG, Dua, K, Kermani, NZ, Eapen, MS, Tiotiu, A, Chung, KF, Caramori, G, Bracke, K, Adcock, IM, Sohal, SS, Wark, PA, Oliver, BG & Hansbro, PM 2022, 'Adverse roles of mast cell chymase-1 in COPD', European Respiratory Journal, vol. 60, no. 6, pp. 2101431-2101431.
View/Download from: Publisher's site
View description>>
BackgroundCOPD is the third leading cause of death worldwide. Cigarette smoke (CS)-induced chronic inflammation inducing airway remodelling, emphysema and impaired lung function is the primary cause. Effective therapies are urgently needed. Human chymase (hCMA)1 and its orthologue mCMA1/mouse mast cell protease (mMCP)5 are exocytosed from activated mast cells and have adverse roles in numerous disorders, but their role in COPD is unknown.MethodsWe evaluated hCMA1 levels in lung tissues of COPD patients. We usedmmcp5-deficient (−/−) mice to evaluate this protease's role and potential for therapeutic targeting in CS-induced experimental COPD. In addition, we usedex vivo/in vitrostudies to define mechanisms.ResultsThe levels of hCMA1 mRNA and CMA1+mast cells were increased in lung tissues from severe compared to early/mild COPD patients, non-COPD smokers and healthy controls. Degranulated mast cell numbers and mMCP5 protein were increased in lung tissues of wild-type mice with experimental COPD.mmcp5−/−mice were protected against CS-induced inflammation and macrophage accumulation, airway remodelling, emphysema and impaired lung function in experimental COPD. CS extract challenge of co-cultures of mast cells from wild-type, but notmmcp5−/−mice with wild-type lung macrophages increased in tumour necrosis factor (TNF)-α release. It also caused the release of CMA1 from human mast cells, and recombinant hCMA-1 induced TNF-α release from human macrophages. Treatment with CMA1 inhibitor potently suppressed these hallmark features of experimental COPD.Conclusion
Madan, J, Ahuja, VK, Dua, K, Samajdar, S, Ramchandra, M & Giri, S 2022, 'PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras', BioDrugs, vol. 36, no. 5, pp. 609-623.
View/Download from: Publisher's site
Manandhar, B, Paudel, KR, Panth, N, Hansbro, P, Oliver, BG & Dua, K 2022, 'Applications of Extracellular Vesicles as A Drug-Delivery System for Chronic Respiratory Diseases', Nanomedicine, vol. 17, no. 12, pp. 817-820.
View/Download from: Publisher's site
Masanam, HB, Perumal, G, Krishnan, S, Singh, SK, Jha, NK, Chellappan, DK, Dua, K, Gupta, PK & Narasimhan, AK 2022, 'Advances and Opportunities In Nanoimaging Agents for the Diagnosis of Inflammatory Lung Diseases', Nanomedicine, vol. 17, no. 25, pp. 1981-2005.
View/Download from: Publisher's site
View description>>
The development of rapid, noninvasive diagnostics to detect lung diseases is a great need after the COVID-2019 outbreak. The nanotechnology-based approach has improved imaging and facilitates the early diagnosis of inflammatory lung diseases. The multifunctional properties of nanoprobes enable better spatial–temporal resolution and a high signal-to-noise ratio in imaging. Targeted nanoimaging agents have been used to bind specific tissues in inflammatory lungs for early-stage diagnosis. However, nanobased imaging approaches for inflammatory lung diseases are still in their infancy. This review provides a solution-focused approach to exploring medical imaging technologies and nanoprobes for the detection of inflammatory lung diseases. Prospects for the development of contrast agents for lung disease detection are also discussed.
Maurya, S, Srivastava, R, Arfin, S, Hawthorne, S, Jha, NK, Agrawal, K, Raj, S, Rathi, B, Kumar, A, Raj, R, Agrawal, S, Paiva-Santos, AC, Malik, AA, Dua, K, Rana, R, Ojha, S, Jha, SK, Sharma, A, Kumar, D, El-Zahaby, SA & Nagar, A 2022, 'Exploring State-Of-The-Art Advances in Targeted Nanomedicines for Managing Acute and Chronic Inflammatory Lung Diseases', Nanomedicine, vol. 17, no. 30, pp. 2245-2264.
View/Download from: Publisher's site
View description>>
Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.
Mishra, N, Ashique, S, Garg, A, Rai, VK, Dua, K, Goyal, A & Bhatt, S 2022, 'Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases', Drug Discovery Today, vol. 27, no. 5, pp. 1431-1440.
View/Download from: Publisher's site
Mittal, KR, Pharasi, N, Sarna, B, Singh, M, Rachana, Haider, S, Singh, SK, Dua, K, Jha, SK, Dey, A, Ojha, S, Mani, S & Jha, NK 2022, 'Nanotechnology-based drug delivery for the treatment of CNS disorders', Translational Neuroscience, vol. 13, no. 1, pp. 527-546.
View/Download from: Publisher's site
View description>>
Abstract Approximately 6.8 million people die annually because of problems related to the central nervous system (CNS), and out of them, approximately 1 million people are affected by neurodegenerative diseases that include Alzheimer’s disease, multiple sclerosis, epilepsy, and Parkinson’s disease. CNS problems are a primary concern because of the complexity of the brain. There are various drugs available to treat CNS disorders and overcome problems with toxicity, specificity, and delivery. Barriers like the blood–brain barrier (BBB) are a challenge, as they do not allow therapeutic drugs to cross and reach their target. Researchers have been searching for ways to allow drugs to pass through the BBB and reach the target sites. These problems highlight the need of nanotechnology to alter or manipulate various processes at the cellular level to achieve the desired attributes. Due to their nanosize, nanoparticles are able to pass through the BBB and are an effective alternative to drug administration and other approaches. Nanotechnology has the potential to improve treatment and diagnostic techniques for CNS disorders and facilitate effective drug transfer. With the aid of nanoengineering, drugs could be modified to perform functions like transference across the BBB, altering signaling pathways, targeting specific cells, effective gene transfer, and promoting regeneration and preservation of nerve cells. The involvement of a nanocarrier framework inside the delivery of several neurotherapeutic agents used in the treatment of neurological diseases is reviewed in this study.
Negi, P, Gautam, S, Sharma, A, Rathore, C, Sharma, L, Upadhyay, N, Tambuwala, MM, Chellappan, DK, Gupta, G, Prasher, P, Dua, K, Agarwal, S & Lal, UR 2022, 'Gastric Ulcer Healing By Chebulinic Acid Solid dispersion-loaded Gastroretentive Raft Systems: Preclinical Evidence', Therapeutic Delivery, vol. 13, no. 2, pp. 81-93.
View/Download from: Publisher's site
View description>>
Background: Chebulinic acid (CA), a component in Terminalia chebula, exhibits antiulcer activity, but has poor aqueous solubility. Raft-forming systems incorporating solid dispersions (SDs) of CA, were developed to overcome its poor biopharmaceutical properties and to prolong the gastric residence time for maximum activity. Methods: SDs were formulated by a solvent evaporation method using Eudragit EPO. Raft formulations consisted of sodium alginate as a polymer. Results: Release of CA in the dissolution medium was 40%, whereas SDs showed 95.45% release. The CA raft system (20 mg/kg) showed curative efficacy in an alcohol-induced gastric ulcer model and increased protection when compared with omeprazole (10 mg/kg) and CA suspension (20 mg/kg). Conclusion: These studies demonstrated SD raft systems to be a promising approach for antiulcer therapy by CA.
Ong, K-L, Cochran, BJ, Manandhar, B, Thomas, S & Rye, K-A 2022, 'HDL maturation and remodelling', Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1867, no. 4, pp. 159119-159119.
View/Download from: Publisher's site
View description>>
Cholesterol in the circulation is mostly transported in an esterified form as a component of lipoproteins. The majority of these cholesteryl esters are produced in nascent, discoidal high density lipoproteins (HDLs) by the enzyme, lecithin:cholesterol acyltransferase (LCAT). Discoidal HDLs are discrete populations of particles that consist of a phospholipid bilayer, the hydrophobic acyl chains of which are shielded from the aqueous environment by apolipoproteins that also confer water solubility on the particles. The progressive LCAT-mediated accumulation of cholesteryl esters in discoidal HDLs generates the spherical HDLs that predominate in normal human plasma. Spherical HDLs contain a core of water insoluble, neutral lipids (cholesteryl esters and triglycerides) that is surrounded by a surface monolayer of phospholipids with which apolipoproteins associate. Although spherical HDLs all have the same basic structure, they are extremely diverse in size, composition, and function. This review is concerned with how the biogenesis of discoidal and spherical HDLs is regulated and the mechanistic basis of their size and compositional heterogeneity. Current understanding of the impact of this heterogeneity on the therapeutic potential of HDLs of varying size and composition is also addressed in the context of several disease states.
Pandey, M, Wen, PX, Ning, GM, Xing, GJ, Wei, LM, Kumar, D, Mayuren, J, Candasamy, M, Gorain, B, Jain, N, Gupta, G & Dua, K 2022, 'Intraductal Delivery of Nanocarriers for Ductal Carcinoma In Situ Treatment: A Strategy to Enhance Localized Delivery', Nanomedicine, vol. 17, no. 24, pp. 1871-1889.
View/Download from: Publisher's site
View description>>
Ductal carcinoma in situ describes the most commonly occurring, noninvasive malignant breast disease, which could be the leading factor in invasive breast cancer. Despite remarkable advancements in treatment options, poor specificity, low bioavailability and dose-induced toxicity of chemotherapy are the main constraint. A unique characteristic of nanocarriers may overcome these problems. Moreover, the intraductal route of administration serves as an alternative approach. The direct nanodrug delivery into mammary ducts results in the accumulation of anticancer agents at targeted tissue for a prolonged period with high permeability, significantly decreasing the tumor size and improving the survival rate. This review focuses mainly on the intraductal delivery of nanocarriers in treating ductal carcinoma in situ, together with potential clinical translational research.
Pandey, NK, Singh, SK, Kumar, B, Gulati, M, Vishwas, S, Khursheed, R, Dureja, H, Chellappan, DK, Jha, NK, Sharma, A, Jha, SK, Gupta, PK, Gupta, S, Gupta, G, Prasher, P & Dua, K 2022, 'Expanding arsenal against diabetes mellitus through nanoformulations loaded with glimepiride and simvastatin: A comparative study', Environmental Science and Pollution Research, vol. 29, no. 34, pp. 51976-51988.
View/Download from: Publisher's site
Paudel, KR, Dua, K, Panth, N, Hansbro, PM & Chellappan, DK 2022, 'Advances in Research With Rutin-Loaded Nanoformulations in Mitigating Lung Diseases', Future Medicinal Chemistry, vol. 14, no. 18, pp. 1293-1295.
View/Download from: Publisher's site
Paudel, KR, Mehta, M, Yin, GHS, Yen, LL, Malyla, V, Patel, VK, Panneerselvam, J, Madheswaran, T, MacLoughlin, R, Jha, NK, Gupta, PK, Singh, SK, Gupta, G, Kumar, P, Oliver, BG, Hansbro, PM, Chellappan, DK & Dua, K 2022, 'Berberine-loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro', Environmental Science and Pollution Research, vol. 29, no. 31, pp. 46830-46847.
View/Download from: Publisher's site
View description>>
AbstractNon-small cell lung cancer (NSCLC) is reported to have a high incidence rate and is one of the most prevalent types of cancer contributing towards 85% of all incidences of lung cancer. Berberine is an isoquinoline alkaloid which offers a broad range of therapeutical and pharmacological actions against cancer. However, extremely low water solubility and poor oral bioavailability have largely restricted its therapeutic applications. To overcome these limitations, we formulated berberine-loaded liquid crystalline nanoparticles (LCNs) and investigated their in vitro antiproliferative and antimigratory activity in human lung epithelial cancer cell line (A549). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), trypan blue staining, and colony forming assays were used to evaluate the anti-proliferative activity, while scratch wound healing assay and a modified Boyden chamber assay were carried out to determine the anti-migratory activity. We also investigated major proteins associated with lung cancer progression. The developed nanoparticles were found to have an average particle size of 181.3 nm with spherical shape, high entrapment efficiency (75.35%) and have shown sustained release behaviour. The most remarkable findings reported with berberine-loaded LCNs were significant suppression of proliferation, inhibition of colony formation, inhibition of invasion or migration via epithelial mesenchymal transition, and proliferation related proteins associated with cancer progression. Our findings suggest that anti-cancer compounds with the problem of poor solubility and bioavailability can be overcome by formulating them into nanotechnology-based delivery systems for better efficacy. Further in-depth investigations into anti-cancer mechanistic research will expand and strengthen the current findings of berberine-LCNs as a potential NSCLC treatment option.
Paudel, KR, Patel, V, Vishwas, S, Gupta, S, Sharma, S, Chan, Y, Jha, NK, Shrestha, J, Imran, M, Panth, N, Shukla, SD, Jha, SK, Devkota, HP, Warkiani, ME, Singh, SK, Ali, MK, Gupta, G, Chellappan, DK, Hansbro, PM & Dua, K 2022, 'Nutraceuticals and COVID‐19: A mechanistic approach toward attenuating the disease complications', Journal of Food Biochemistry, vol. 46, no. 12, p. e14445.
View/Download from: Publisher's site
View description>>
Nutraceuticals have emerged as potential compounds to attenuate the COVID-19 complications. Precisely, these food additives strengthen the overall COVID treatment and enhance the immunity of a person. Such compounds have been used at a large scale, in almost every household due to their better affordability and easy access. Therefore, current research is focused on developing newer advanced formulations from potential drug candidates including nutraceuticals with desirable properties viz, affordability, ease of availability, ease of administration, stability under room temperature, and potentially longer shelf-lives. As such, various nutraceutical-based products such as compounds could be promising agents for effectively managing COVID-19 symptoms and complications. Most importantly, regular consumption of such nutraceuticals has been shown to boost the immune system and prevent viral infections. Nutraceuticals such as vitamins, amino acids, flavonoids like curcumin, and probiotics have been studied for their role in the prevention of COVID-19 symptoms such as fever, pain, malaise, and dry cough. In this review, we have critically reviewed the potential of various nutraceutical-based therapeutics for the management of COVID-19. We searched the information relevant to our topic from search engines such as PubMed and Scopus using COVID-19, nutraceuticals, probiotics, and vitamins as a keyword. Any scientific literature published in a language other than English was excluded. PRACTICAL APPLICATIONS: Nutraceuticals possess both nutritional values and medicinal properties. They can aid in the prevention and treatment of diseases, as well as promote physical health and the immune system, normalizing body functions, and improving longevity. Recently, nutraceuticals such as probiotics, vitamins, polyunsaturated fatty acids, trace minerals, and medicinal plants have attracted considerable attention and are widely regarded as potential alternatives to current the...
Penm, J, Narayan, S, Alffenaar, J, Johnson, JL, Mirkov, S, Page, AT, Pont, LG & Patanwala, AE 2022, 'A benchmarking scoping review of research output from hospital pharmacy departments in Australia', Journal of Pharmacy Practice and Research, vol. 52, no. 4, pp. 275-282.
View/Download from: Publisher's site
View description>>
AbstractAimTo benchmark annual research output from hospital pharmacy departments in Australian principal referral hospitals.Data sourcesEmbase, Medline, and Scopus.Study selectionAll 29 principal referral hospitals listed by the Australian Institute of Health and Welfare were searched using the institution field from 2018–2020. Articles were included if an author was affiliated with a hospital pharmacy department. Conference abstracts, letters, narrative reviews, opinions, commentaries, or editorials were excluded.ResultsA total of 261 research articles were identified from 27 principal referral hospital pharmacy departments from 2018–2020. Median research output over 3 years was five (interquartile range, 3–9) articles. In terms of annual research, hospital pharmacy departments in the 50th and 90th percentile for total publication output published two and ten original research articles every year, respectively. Overall, 56% (n = 145) of the published studies were observational, 35% (n = 90) had a first author with a pharmacy department affiliation, 97% (n = 252) had at least one author with a university affiliation, and in 5% (n = 12) of the articles there was more than one hospital pharmacy department affiliation.ConclusionOn average, hospital pharmacy departments in Australian principal referral hospitals publish two original research articles every year. Nearly all of these articles are published in collaborations with universities.
Perumalsamy, H, Shanmugam, R, Kim, J-R, Anandapadmanaban, G, Huq, MA, Dua, K, Chellappan, DK, Yoon, TH & Balusamy, SR 2022, '[Retracted] Nanoemulsion and Encapsulation Strategy of Hydrophobic Oregano Essential Oil Increased Human Prostate Cancer Cell Death via Apoptosis by Attenuating Lipid Metabolism', Bioinorganic Chemistry and Applications, vol. 2022, no. 1, pp. 1-11.
View/Download from: Publisher's site
View description>>
Origanum vulgare essential oil (EO) is traditionally well‐known for its aromatic properties and biomedical applications, including anticancer. This was the first report where oregano essential oil‐based nano emulsion (OENE) was synthesized for studying its effects on prostate cancer cell lines (PC3). At first, we have synthesized OENE and characterized using various spectroscopic analyses. The toxicity and inhibitory concentration (IC50) of OENE toward prostate cancer by MTT analysis were performed. The lipid biogenesis mediated, molecular target pathway analyses were performed using fluorescence cellular staining techniques, real‐time RT‐PCR, or western blotting analysis. OENE showed IC50 at 13.82 µg/mL and significantly induced distinct morphological changes, including cell shrinkage, cell density, and cell shape reduction. In addition, OENE could also significantly decreased lipid droplet accumulation which was confirmed by studying mRNA transcripts of 3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR) (0.31‐fold), fatty acid synthase (FASN) (0.18‐fold), and sterol regulatory element‐binding protein (SREPB1) (0.11‐fold), respectively. Furthermore, there is a significant upregulation BAX (BCL2 associated X) and caspase 3 expressions. Nevertheless, OENE decreased the transcript level of BCL2 (B‐cell lymphoma 2), thus resulting in apoptosis. Overall, our present work demonstrated that OENE could be a therapeutic target for the treatment of prostate cancer and warrants in vivo studies.
Prasher, P, Sharma, M, Kumar Singh, S, Gulati, M, Kumar, D, Gupta, G, Kumar Chellappan, D, Gregory George Oliver, B, Wich, PR & Dua, K 2022, 'Versatility of acetalated dextran in nanocarriers targeting respiratory diseases', Materials Letters, vol. 323, pp. 132600-132600.
View/Download from: Publisher's site
Prasher, P, Sharma, M, Singh, SK, Gulati, M, Jha, NK, Gupta, PK, Gupta, G, Chellappan, DK, Zacconi, F, de Jesus Andreoli Pinto, T, Chan, Y, Liu, G, Paudel, KR, Hansbro, PM, George Oliver, BG & Dua, K 2022, 'Targeting mucus barrier in respiratory diseases by chemically modified advanced delivery systems', Chemico-Biological Interactions, vol. 365, pp. 110048-110048.
View/Download from: Publisher's site
Prasher, P, Sharma, M, Singh, SK, Gulati, M, Patravale, V, Oliver, BG & Dua, K 2022, 'Mucoadhesive Particles: An Emerging Toolkit for Advanced Respiratory Drug Delivery', Nanomedicine, vol. 17, no. 12, pp. 821-826.
View/Download from: Publisher's site
Prasher, P, Sharma, M, Singh, SK, Haghi, M, MacLoughlin, R, Chellappan, DK, Gupta, G, Paudel, KR, Hansbro, PM, George Oliver, BG, Wich, PR & Dua, K 2022, 'Advances and applications of dextran-based nanomaterials targeting inflammatory respiratory diseases', Journal of Drug Delivery Science and Technology, vol. 74, pp. 103598-103598.
View/Download from: Publisher's site
Quetglas-Llabrés, MM, Quispe, C, Herrera-Bravo, J, Catarino, MD, Pereira, OR, Cardoso, SM, Dua, K, Chellappan, DK, Pabreja, K, Satija, S, Mehta, M, Sureda, A, Martorell, M, Satmbekova, D, Yeskaliyeva, B, Sharifi-Rad, J, Rasool, N, Butnariu, M, Bagiu, IC, Bagiu, RV, Calina, D & Cho, WC 2022, 'Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Aspects', Oxidative Medicine and Cellular Longevity, vol. 2022, pp. 1-10.
View/Download from: Publisher's site
View description>>
Bergapten (BP) or 5-methoxypsoralen (5-MOP) is a furocoumarin compound mainly found in bergamot essential oil but also in other citrus essential oils and grapefruit juice. This compound presents antibacterial, anti-inflammatory, hypolipemic, and anticancer effects and is successfully used as a photosensitizing agent. The present review focuses on the research evidence related to the therapeutic properties of bergapten collected in recent years. Many preclinical and in vitro studies have been evidenced the therapeutic action of BP; however, few clinical trials have been carried out to evaluate its efficacy. These clinical trials with BP are mainly focused on patients suffering from skin disorders such as psoriasis or vitiligo. In these trials, the administration of BP (oral or topical) combined with UV irradiation induces relevant lesion clearance rates. In addition, beneficial effects of bergamot extract were also observed in patients with altered serum lipid profiles and in people with nonalcoholic fatty liver. On the contrary, there are no clinical trials that investigate the possible effects on cancer. Although the bioavailability of BP is lower than that of its 8-methoxypsoralen (8-MOP) isomer, it has fewer side effects allowing higher concentrations to be administered. In conclusion, although the use of BP has therapeutic applications on skin disorders as a sensitizing agent and as components of bergamot extract as hypolipemic therapy, more trials are necessary to define the doses and treatment guidelines and its usefulness against other pathologies such as cancer or bacterial infections.
Rahman, MM, Islam, MR, Mim, SA, Sultana, N, Chellappan, DK, Dua, K, Kamal, MA, Sharma, R & Emran, TB 2022, 'Insights into the Promising Prospect of G Protein and GPCR-Mediated Signaling in Neuropathophysiology and Its Therapeutic Regulation', Oxidative Medicine and Cellular Longevity, vol. 2022, pp. 1-22.
View/Download from: Publisher's site
View description>>
G protein-coupled receptors (GPCRs) are intricately involved in the conversion of extracellular feedback to intracellular responses. These specialized receptors possess a crucial role in neurological and psychiatric disorders. Most nonsensory GPCRs are active in almost 90% of complex brain functions. At the time of receptor phosphorylation, a GPCR pathway is essentially activated through a G protein signaling mechanism via a G protein-coupled receptor kinase (GRK). Dopamine, an important neurotransmitter, is primarily involved in the pathophysiology of several CNS disorders; for instance, bipolar disorder, schizophrenia, Parkinson’s disease, and ADHD. Since dopamine, acetylcholine, and glutamate are potent neuropharmacological targets, dopamine itself has potential therapeutic effects in several CNS disorders. GPCRs essentially regulate brain functions by modulating downstream signaling pathways. GPR6, GPR52, and GPR8 are termed orphan GPCRs because they colocalize with dopamine D1 and D2 receptors in neurons of the basal ganglia, either alone or with both receptors. Among the orphan GPCRs, the GPR52 is recognized for being an effective psychiatric receptor. Various antipsychotics like aripiprazole and quetiapine mainly target GPCRs to exert their actions. One of the most important parts of signal transduction is the regulation of G protein signaling (RGS). These substances inhibit the activation of the G protein that initiates GPCR signaling. Developing a combination of RGS inhibitors with GPCR agonists may prove to have promising therapeutic potential. Indeed, several recent studies have suggested that GPCRs represent potentially valuable therapeutic targets for various psychiatric disorders. Molecular biology and genetically modified animal model studies recommend that these enriched GPCRs may also act as potential therapeutic psychoreceptors. Neurotransmitter and neuropeptide GPCR malfunction in the frontal cortex and limbic-related regions,...
Raj, SK, Babu, MR, Vishwas, S, Chaitanya, MVNL, Harish, V, Gupta, G, Chellappan, DK, Dua, K & Singh, SK 2022, 'An overview of recent advances in insulin delivery and wearable technology for effective management of diabetes', Journal of Drug Delivery Science and Technology, vol. 75, pp. 103728-103728.
View/Download from: Publisher's site
Ramanunny, AK, Wadhwa, S, Gulati, M, Gupta, S, Porwal, O, Jha, NK, Gupta, PK, Kumar, D, Prasher, P, Dua, K, Saqr, AA, Almawash, S & Singh, SK 2022, 'Development and validation of RP-HPLC method for 1΄-Acetoxychavicol acetate (ACA) and its application in optimizing the yield of ACA during its isolation from Alpinia galanga extract as well as its quantification in nanoemulsion', South African Journal of Botany, vol. 149, pp. 887-898.
View/Download from: Publisher's site
Ramanunny, AK, Wadhwa, S, Gulati, M, Vishwas, S, Khursheed, R, Paudel, KR, Gupta, S, Porwal, O, Alshahrani, SM, Jha, NK, Chellappan, DK, Prasher, P, Gupta, G, Adams, J, Dua, K, Tewari, D & Singh, SK 2022, 'Journey of Alpinia galanga from kitchen spice to nutraceutical to folk medicine to nanomedicine', Journal of Ethnopharmacology, vol. 291, pp. 115144-115144.
View/Download from: Publisher's site
Ramanunny, AK, Wadhwa, S, Kumar Singh, S, Kumar, B, Gulati, M, Kumar, A, Almawash, S, Al Saqr, A, Gowthamarajan, K, Dua, K, Singh, H, Vishwas, S, Khursheed, R, Rahana Parveen, S, Venkatesan, A, Paudel, KR, Hansbro, PM & Kumar Chellappan, D 2022, 'Topical non-aqueous nanoemulsion of Alpinia galanga extract for effective treatment in psoriasis: In vitro and in vivo evaluation', International Journal of Pharmaceutics, vol. 624, pp. 121882-121882.
View/Download from: Publisher's site
Rohilla, S, Awasthi, R, Mehta, M, Chellappan, DK, Gupta, G, Gulati, M, Singh, SK, Anand, K, Oliver, BG, Dua, K & Dureja, H 2022, 'Preparation and Evaluation of Gefitinib Containing Nanoliposomal Formulation for Lung Cancer Therapy', BioNanoScience, vol. 12, no. 1, pp. 241-255.
View/Download from: Publisher's site
Runtsch, MC, Angiari, S, Hooftman, A, Wadhwa, R, Zhang, Y, Zheng, Y, Spina, JS, Ruzek, MC, Argiriadi, MA, McGettrick, AF, Mendez, RS, Zotta, A, Peace, CG, Walsh, A, Chirillo, R, Hams, E, Fallon, PG, Jayaraman, R, Dua, K, Brown, AC, Kim, RY, Horvat, JC, Hansbro, PM, Wang, C & O’Neill, LAJ 2022, 'Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages', Cell Metabolism, vol. 34, no. 3, pp. 487-501.e8.
View/Download from: Publisher's site
Sarena, P, Sharma, A, Urmera, MT, Tambuwala, MM, Aljabali, AAA, Chellappan, DK, Dua, K, Taliyan, R & Goyal, R 2022, 'Chronic Light-Distorted Glutamate-Cortisol Signaling, Behavioral and Histological Markers, and Induced Oxidative Stress and Dementia: An Amelioration by Melatonin', ACS Chemical Neuroscience, vol. 13, no. 11, pp. 1604-1614.
View/Download from: Publisher's site
Shah, JN, Guo, G-Q, Krishnan, A, Ramesh, M, Katari, NK, Shahbaaz, M, Abdellattif, MH, Singh, SK & Dua, K 2022, 'Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19', Therapies, vol. 77, no. 3, pp. 319-328.
View/Download from: Publisher's site
Shaikh, MAJ, Alharbi, KS, Almalki, WH, Imam, SS, Albratty, M, Meraya, AM, Alzarea, SI, Kazmi, I, Al-Abbasi, FA, Afzal, O, Altamimi, ASA, Singh, Y, Singh, SK, Dua, K & Gupta, G 2022, 'Sodium alginate based drug delivery in management of breast cancer', Carbohydrate Polymers, vol. 292, pp. 119689-119689.
View/Download from: Publisher's site
Sharma, A, Dulta, K, Nagraik, R, Dua, K, Singh, SK, Chellappan, DK, Kumar, D & Shin, D-S 2022, 'Potentialities of aptasensors in cancer diagnosis', Materials Letters, vol. 308, pp. 131240-131240.
View/Download from: Publisher's site
Sharma, N, Kulkarni, GT, Bhatt, AN, Satija, S, Singh, L, Sharma, A, Dua, K, Karwasra, R, Khan, AA, Ahmad, N & Raza, K 2022, 'Therapeutic Options for the SARS-CoV-2 Virus: Is There a Key in Herbal Medicine?', Natural Product Communications, vol. 17, no. 9, pp. 1934578X2211263-1934578X2211263.
View/Download from: Publisher's site
View description>>
SARS-CoV-2 has been responsible for over 500 million cumulative cases all over the world since December 2019 and has marked the third introduction of a highly pathogenic virus after SARS-CoV and MERS-CoV. This virus is in a winning situation because scientists are still racing to explore effective therapeutics, vaccines, and event treatment regimens. In view of progress in current disease management, until now none of the preventive/treatment measures can be considered entirely effective to treat SARS-CoV-2 infection. Therefore, it is required to look up substitute ways for the management of this disease. In this context, herbal medicines could be a good choice. This article emphasizes the antiviral potential of some herbal constituents which further can be a drug of choice in SARS-CoV-2 treatment. This article may be a ready reference for discovering natural lead compounds and targets in SARS-CoV-2 associated works.
Sheikholeslami, B, Lam, NW, Dua, K & Haghi, M 2022, 'Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate', Life Sciences, vol. 300, pp. 120574-120574.
View/Download from: Publisher's site
Shukla, MK, Dubey, A, Pandey, S, Singh, SK, Gupta, G, Prasher, P, Chellappan, DK, Oliver, BG, Kumar, D & Dua, K 2022, 'Managing Apoptosis in Lung Diseases using Nano-assisted Drug Delivery System', Current Pharmaceutical Design, vol. 28, no. 39, pp. 3202-3211.
View/Download from: Publisher's site
View description>>
Abstract:Several factors exist that limit the efficacy of lung cancer treatment. These may be tumor-specificdelivery of therapeutics, airway geometry, humidity, clearance mechanisms, presence of lung diseases, andtherapy against tumor cell resistance. Advancements in drug delivery using nanotechnology based multifunctionalnanocarriers, have emerged as a viable method for treating lung cancer with more efficacy and fewer adverseeffects. This review does a thorough and critical examination of effective nano-enabled approaches forlung cancer treatment, such as nano-assisted drug delivery systems. In addition, to therapeutic effectiveness,researchers have been working to determine several strategies to produce nanotherapeutics by adjusting thesize, drug loading, transport, and retention. Personalized lung tumor therapies using sophisticated nano modalitieshave the potential to provide great therapeutic advantages based on individual unique genetic markers anddisease profiles. Overall, this review provides comprehensive information on newer nanotechnological prospectsfor improving the management of apoptosis in lung cancer.
Shukla, MK, Singh, SK, Pandey, S, Gupta, PK, Choudhary, A, Jindal, DK, Dua, K & Kumar, D 2022, 'Potential Immunomodulatory Activities of Plant Products', South African Journal of Botany, vol. 149, pp. 937-943.
View/Download from: Publisher's site
Shukla, SD, Shastri, MD, Vanka, SK, Jha, NK, Dureja, H, Gupta, G, Chellappan, DK, Oliver, BG, Dua, K & Walters, EH 2022, 'Correction to: Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce rhinovirus-induced acute exacerbations in chronic respiratory diseases', Inflammopharmacology, vol. 30, no. 4, pp. 1477-1477.
View/Download from: Publisher's site
Shukla, SD, Shastri, MD, Vanka, SK, Jha, NK, Dureja, H, Gupta, G, Chellappan, DK, Oliver, BG, Dua, K & Walters, EH 2022, 'Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce rhinovirus-induced acute exacerbations in chronic respiratory diseases', Inflammopharmacology, vol. 30, no. 3, pp. 725-735.
View/Download from: Publisher's site
View description>>
AbstractThe chronic respiratory non-communicable diseases, asthma and chronic obstructive pulmonary disease (COPD) are among the leading causes of global mortality and morbidity. Individuals suffering from these diseases are particularly susceptible to respiratory infections caused by bacterial and/or viral pathogens, which frequently result in exacerbation of symptoms, lung function decline, frequent hospital emergency visits and increased socioeconomic burden. Human rhinoviruses (HRV) remain the major viral pathogen group implicated in exacerbations of both asthma and COPD. The rhinoviral entry into the host lung epithelium is facilitated primarily by the adhesion site (“receptor”) intercellular adhesion molecule-1 (ICAM-1), coincidentally expressed on the respiratory epithelium in these conditions. Multiple observations of increased airway ICAM-1 protein in asthmatics, smokers and smoking-related COPD have been recorded in the literature. However, the lack of robust therapies for COPD in particular has triggered a renewed interest in assessing receptor antagonism-based anti-viral strategies for treatment of intercurrent viral infections in those with pre-existing chronic lung diseases. Given the crucial role ICAM-1 plays in facilitating HRV adhesion and, thus, transmissibility to the host respiratory system, as well as the up-regulation of ICAM-1 by smoking, we summarize the role of HRV in smoking-induced COPD and especially highlight the role of ICAM-1 in epithelial viral adhesion and chronic lung disease progression. Further, the review also sheds light specifically on evolving precision therapeutic strategies in blocking ICAM-1 for preventing viral adhesion and exacerbations of COPD.
Tan, CL, Chan, Y, Candasamy, M, Chellian, J, Madheswaran, T, Sakthivel, LP, Patel, VK, Chakraborty, A, MacLoughlin, R, Kumar, D, Verma, N, Malyla, V, Gupta, PK, Jha, NK, Thangavelu, L, Devkota, HP, Bhatt, S, Prasher, P, Gupta, G, Gulati, M, Singh, SK, Paudel, KR, Hansbro, PM, Oliver, BG, Dua, K & Chellappan, DK 2022, 'Unravelling the molecular mechanisms underlying chronic respiratory diseases for the development of novel therapeutics via in vitro experimental models', European Journal of Pharmacology, vol. 919, pp. 174821-174821.
View/Download from: Publisher's site
Thangavelu, L, Geetha, RV, Devaraj, E, Dua, K, Chellappan, DK & Balusamy, SR 2022, 'Acacia catechu seed extract provokes cytotoxicity via apoptosis by intrinsic pathway in HepG2 cells', Environmental Toxicology, vol. 37, no. 3, pp. 446-456.
View/Download from: Publisher's site
View description>>
AbstractAcacia catechu Willd (Fabaceae) is a thorny tree widely distributed in India and commonly used as traditional Ayurvedic medicine for various ailments. The current study evaluates the cytotoxic potentials of A. catechu ethanolic seed extract (ACSE) in HepG2 cells, a human hepatocellular carcinoma cell line. The HepG2 cells were treated with 0.1, 0.3, 1, 3, 10, 30, 100, 300 and 1000 μg/ml of ACSE and the cytotoxic effect was evaluated by MTT and lactate dehydrogenase (LDH) leakage assays. The IC50 of ACSE was found at 77.04 μg/ml and therefore, further studies were carried out with the concentrations of 35 and 70 μg/ml. The intracellular reactive oxygen species (ROS) generation and apoptosis‐related morphological changes were evaluated. Gene expressions of Bax, Bcl‐2, cytochrome C (Cyt‐c), caspases‐9 and 3 were analyzed by qPCR. The ACSE treatments caused LDH leakage was associated with an increased ROS generation. The increased ROS generation was associated with the downregulation of intracellular antioxidant enzyme superoxide dismutase and reduced glutathione content. AO/EB and PI staining also confirmed chromatin condensation and apoptosis. The flow cytometric analysis showed an accumulation of HepG2 cells at sub G0/G1 (apoptotic) phase upon ACSE treatments. The ACSE induced cytotoxicity and oxidative stress were related to increased apoptotic marker gene expressions such as Bax, Cyt‐c, caspase‐9 and 3, and decreased anti‐apoptotic marker Bcl‐2. The current finding suggests that ACSE has apoptosis‐inducing potential via the mitochondrial pathway in HepG2 cells.
Thangavelu, L, Veeraragavan, GR, Mallineni, SK, Devaraj, E, Parameswari, RP, Syed, NH, Dua, K, Chellappan, DK, Balusamy, SR & Bhawal, UK 2022, '[Retracted] Role of Nanoparticles in Environmental Remediation: An Insight into Heavy Metal Pollution from Dentistry', Bioinorganic Chemistry and Applications, vol. 2022, no. 1, pp. 1-13.
View/Download from: Publisher's site
View description>>
Environmental damage is without a doubt one of the most serious issues confronting society today. As dental professionals, we must recognize that some of the procedures and techniques we have been using may pose environmental risks. The usage and discharge of heavy metals from dental set‐ups pollute the environment and pose a serious threat to the ecosystem. Due to the exclusive properties of nanosized particles, nanotechnology is a booming field that is being extensively studied for the remediation of pollutants. Given that the nanoparticles have a high surface area to volume ratio and significantly greater reactivity, they have been greatly considered for environmental remediation. This review aims at identifying the heavy metal sources and their environmental impact in dentistry and provides insights into the usage of nanoparticles in environmental remediation. Although the literature on various functions of inorganic nanoparticles in environmental remediation was reviewed, the research is still confined to laboratory set‐ups and there is a need for more studies on the usage of nanoparticles in environmental remediation.
Thirugnanasambandham, I, Radhakrishnan, A, Kuppusamy, G, Kumar Singh, S & Dua, K 2022, 'Peptidylarginine deiminase-4: Medico-formulative strategy towards management of rheumatoid arthritis', Biochemical Pharmacology, vol. 200, pp. 115040-115040.
View/Download from: Publisher's site
Tomar, D, Singh, PK, Hoque, S, Modani, S, Sriram, A, Kumar, R, Madan, J, Khatri, D & Dua, K 2022, 'Amorphous systems for delivery of nutraceuticals: challenges opportunities', Critical Reviews in Food Science and Nutrition, vol. 62, no. 5, pp. 1204-1221.
View/Download from: Publisher's site
View description>>
Amorphous solid products have recently gained a lot of attention as key solutions to improve the solubility and bioavailability of poorly soluble nutraceuticals. A pure amorphous drug is a high-energy form; physically/chemically unstable and so easily gets recrystallized into the less soluble crystalline form limiting solubility and bioavailability issues. Amorphous solid dispersion and co-amorphous are new formulation approach that stabilized unstable amorphous form through different mechanisms such as preventing mobility, high glass transition temperature and molecular interaction. Nutraceuticals have been received the utmost importance due to their health benefits. However, most of these compounds have been associated with poor oral bioavailability due to poor solubility, high lipophilicity, high melting point, poor permeability, degradability and rapid metabolism in the gastrointestinal tract (GIT) which limits its health benefits. This review provides us a systematic application of amorphous systems to the delivery of poorly soluble nutraceuticals, with the aim of overcoming their pharmacokinetic limitations and improved pharmacological potential. In particular, it describes the challenges associated with delivery of oral nutraceuticals, various methods involved in the preparation and characterization of amorphous systems and permeability enhancement of nutraceuticals are in detail.
Usman, MB, Ojha, S, Jha, SK, Chellappan, DK, Gupta, G, Singh, SK, Dua, K, Roychoudhury, S, Kumar, N, Khan, FA, Dureja, H, Upadhye, V, Zacconi, F, Prasanna, P, Kesari, KK, Ashraf, GM, Alexiou, A & Jha, NK 2022, 'Biological databases and tools for neurological disorders', Journal of Integrative Neuroscience, vol. 21, no. 1, pp. 041-041.
View/Download from: Publisher's site
View description>>
Computational approaches to study of neuronal impairment is rapidly evolving, as experiments and intuition alone do not explain the complexity of the brain system. An overwhelming increase in the amount of new data from both theory and computational modeling necessitate the development of databases and tools for analysis, visualization and interpretation of neuroscience data. To ensure the sustainability of this development, consistent update and training of young professionals is imperative. For this purpose, relevant articles, chapters, and modules are essential to keep abreast of developments. This review seeks to outline the biological databases and analytical tools along with their applications. It is envisaged that such knowledge could provide a “training recipe” for young scientists and a guide for professionals and researchers in neuroscience.
Vadivalagan, C, Shitut, A, Kamalakannan, S, Chen, R-M, Serrano-Aroca, Á, Mishra, V, Aljabali, AAA, Singh, SK, Chellappan, DK, Gupta, G, Dua, K, El-Tanani, M, Tambuwala, MM & Krishnan, A 2022, 'Exosomal mediated signal transduction through artificial microRNA (amiRNA): A potential target for inhibition of SARS-CoV-2', Cellular Signalling, vol. 95, pp. 110334-110334.
View/Download from: Publisher's site
Verma, N, Arora, V, Awasthi, R, Chan, Y, Jha, NK, Thapa, K, Jawaid, T, Kamal, M, Gupta, G, Liu, G, Paudel, KR, Hansbro, PM, George Oliver, BG, Singh, SK, Chellappan, DK, Dureja, H & Dua, K 2022, 'Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis', Journal of Drug Delivery Science and Technology, vol. 75, pp. 103690-103690.
View/Download from: Publisher's site
Vishwas, S, Singh, SK, Gulati, M, Awasthi, A, Khursheed, R, Corrie, L, Kumar, R, Collet, T, Loebenberg, R, Porwal, O, Gupta, S, Jha, NK, Gupta, PK, Devkota, HP, Chellappan, DK, Gupta, G, Adams, J & Dua, K 2022, 'Harnessing the therapeutic potential of fisetin and its nanoparticles: Journey so far and road ahead', Chemico-Biological Interactions, vol. 356, pp. 109869-109869.
View/Download from: Publisher's site
